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ABSTRACT 
Ming Yu: The Importance of ERBB Receptor Tyrosine Kinase Signaling in  
Colorectal Cancer Implications for EGFR-Targeted Therapies 
 
(Under the direction of Dr. David W. Threadgill) 
 
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the 
United States. Our current understanding of the molecular pathways associated with this 
malignancy has led to the development of novel molecule targeted therapies, exemplified 
by small molecule inhibitors and monoclonal antibodies targeting the epidermal growth 
factor receptor (EGFR/ERBB1). EGFR is a member of the ERBB family of receptor 
tyrosine kinases consisting of EGFR(ERBB1), ERBB2, ERBB3 and ERBB4. They are 
transmembrane receptors to elicit cellular signaling pathways in response to extracellular 
stimuli. Upon ligand binding, ERBB family receptors dimerize to phosphorylate the 
cytoplasmic kinase domain, resulting in activation of complex downstream signaling 
cascades, among which the RAS/MEK/MAPK pathway delivers pro-proliferative signals 
and the PI3K/ATK/mTOR cascade act as a pro-survival pathway. The ERBB family 
members play a pivotal role in many aspects of cellular biology. As such, misregulation or 
dysfunction of ERBB receptors has been implicated in many disease states, in particular 
cancers of epithelial tissues, making the ERBB pathways valuable targets for 
pharmacological inhibition in cancer treatment. For EGFR-targeted therapies, although 
preclinical and early clinical studies presented encouraging results, the large-scale clinical 
trials clearly demonstrate that the majority of patients do not respond. This discrepancy 
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demonstrates that little is known about the mechanisms underlying tumor response to 
EGFR-targeted therapies. In this study, by using ApcMin mouse models of familial CRC, we 
generated mice with Egfr deletion exclusively in the intestinal epithelium and 
demonstrated that although EGFR signaling is critical for establishment of most intestinal 
tumor, tumors can arise independent of EGFR activity. Moreover, we identified gene 
expression signatures of EGFR-independent tumors and provided evidence for ERBB3 
activity in mediating compensatory pathways. Consequently, we further established the 
importance of ERBB3 pathway during intestinal tumorigenesis with both ApcMin mouse 
models of familial CRC and azoxymethane (AOM) model of sporadic CRC. Finally, by 
utilizing mice harboring a hypomorphic Egfr allele on four different strain backgrounds, 
we demonstrated the strong background modulation of tumor response to EGFR inhibition. 
These studies may advance understanding of ERBB biology during intestinal 
tumorigenesis and help design better therapies in combination with EGFR-targeted agents.
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Chapter 1 General introduction
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1.1 Introduction to colorectal cancer 
Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies in 
industrialized countries. The incidence of CRC in the US during 2007 will be 
approximately 153,760 cases (Jemal et al., 2007). Over the past decade, CRC death rates 
have decreased slightly due to progress made in early detection, diagnosis and treatment 
(Figure 1-1). Nonetheless, CRC remains the second leading cause of cancer-related deaths 
in the U.S., accounting for 52,180 deaths in 2007 (Jemal et al., 2007).  
The risk factors associated with CRC can be categorized into non-genetic and 
genetic risk factors. Among the non-genetic factors are age (by the age 70, about 50% of 
the Western population will develop adenomatous polyps), a Western style diet (high 
fat/low fiber), a sedentary life style, obesity and incidences of inflammatory bowel disease. 
Although several genes that contribute to familial cases of CRC are known, only a few 
susceptibility genes have been identified for sporadic CRC; the fact that individuals with a 
family history of CRC are more likely to develop CRC strongly indicates the existence of 
genetic risk factors. 
1.1.1 Genetic predisposition to CRC 
CRC cases with known causative mutations, classified as ‘familial CRC’, account 
for about 20% of CRC. The most common inherited forms of CRC are familial 
adenomatous polyposis (FAP) and hereditary non-polyposis CRC (HNPCC). The roles of 
genetic defects underlying these two conditions have been well characterized. In contrast, 
our understanding of low-penetrance mutations that contribute to the remaining familial 
CRC and the majority of CRC that arise sporadically is still evolving. Identifying these 
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low-penetrance mutations would help to identify genetically predisposed individuals with 
an elevated risk for CRC in order for early preventive or therapeutic intervention. 
The Familial adenomatous polyposis (FAP).  
FAP accounts for less than 1% of CRC cases. FAP patients develop hundreds to 
thousands of polyps as early as adolescence making these patients at a high risk for 
developing CRC. The molecular mechanism causing FAP is a germline mutation in the 
APC (adenomatous polyposis coli) gene (Groden et al., 1991; Nishisho et al., 1991). The 
APC gene is a tumor suppressor gene in that it is a negative regulator of the WNT-
signaling pathway through its role in the destruction of β-catenin (Munemitsu et al., 1995; 
Rubinfeld et al., 1995). In cells loosing the remaining wildtype APC, β-catenin is no longer 
degraded, causing its accumulation and translocation into the nucleus where it functions as 
a transcription co-activator with the T-cell factor (TCF) and lymphoid enhancer factor 
(LEF) family of transcription factors (Behrens et al., 1996; Molenaar et al., 1996). In APC 
mutant cells, the β-catenin/TCF/LEF complex activates the transcription of genes that are 
involved in cellular transformation, including p16INK4a, c-MYC, and cyclin D1 (Korinek et 
al., 1997; Morin et al., 1997). In APC mutant colonocytes, excess cytosolic β-catenin also 
forms complexes with E-cadherin, leading to enhanced cell-cell adhesion. These tight 
cellular junctions likely slow the migration of colonocytes to the tip of villus where they 
normally undergo anoikis. Thus APC mutant colonocytes linger within the crypts, 
contributing to the broadening of the proliferative zone (Nathke et al., 1996; Wong et al., 
1996). With the accumulation of other mutations, such as in KRAS, CRC is initiated 
(Dlugosz et al., 1997).  
Hereditary non-polyposis colorectal cancer (HNPCC) 
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HNPCC, also known as Lynch Syndrome, predisposes individuals to CRC in 
addition to cancers in other organs such as stomach, ovaries, small bowel, endometrium, 
uroepithelial epithelium, and the brain (Lynch et al., 1977). HNPCC accounts for 3 to 6% 
of all CRC cases (Lynch and de la Chapelle, 1999; Peltomaki et al., 2001). Affected 
individuals develop one or several polyps. These polyps have a higher frequency of 
progressing to malignancy because of germline mutations in DNA mismatch repair 
(MMR) genes including MSH2, MLH1, PMS1, PMS2, which underlie 90% of Lynch 
Syndrome cases. Deficiency in the MMR system leads to a high frequency of DNA 
replication errors and changes in short repeated DNA sequences, a condition known as 
microsatelite instability. 
The sporadic CRC 
The majority of CRC cases are believed to arise sporadically. However, genetic 
factors still contribute to sporadic CRC. Several low-penetrance alleles in sporadic CRC 
have been identified, including the I1307K mutation in the APC gene, the TGFBR1*6Ala 
allele, HRAS1*VNTR and BLM*Ash (Kondo and Issa, 2004). Risk factors such as age and 
diet could modulate the onset of CRC in these genetically predisposed individuals, 
possibly through epigenetic changes.  
1.1.2 Molecular complexity of CRC 
Understanding the molecular complexity of CRC is required to improve prevention 
and treatment. The development of CRC is generally thought of as a well defined sequence 
of events involving a complex series of genetic and epigenetic alterations, resulting in 
distinct pathological changes - from aberrant crypt focus (ACF) or hyperplasia to benign 
adenoma, carcinoma and finally metastasis (Kinzler and Vogelstein, 1996)(Figure 1-2). 
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This cumulative multi-stage process usually occurs over many years. In individuals with 
inherited mutations, the time course of initiation and/or progression to malignancy can be 
significantly shorter. For example, FAP patients have a much higher rate of initiation from 
normal epithelium to benign polyps, although the progression rate to carcinoma is not 
altered. Conversely, in HNPCC patients the initiation step appears unchanged compared to 
sporadic cancers, but once initiated the progression from polyps into malignancy is much 
sooner.  
Recently, gene expression profiling of 100 human CRC adenomas revealed that 
human colon cancers exhibit gene expression patterns strikingly similar to those of 
embryonic colon development (Kaiser et al., 2007), highlighting the notion that cancer and 
normal embryonic development share common gene regulatory networks.  
Distinct from classical genetic alterations, epigenetic abnormalities also contribute 
to CRC carcinogenesis. Abnormal genome-wide hypomethylation is particularly frequent 
in CRC, associated with over-expression of proto-oncogenes (Issa, 2000; Kondo and Issa, 
2004). In contrast to genome-wide hypomethylation, focal hypermethylation can result in 
transcriptional silencing of tumor suppressor genes (Feinberg and Tycko, 2004; Greger et 
al., 1989). Indeed, promoter hypermethylation in CRC have been reported for important 
tumor suppressor genes including APC, LKB1, p16INK4a, hMLH1, and TIMP3 (Kondo and 
Issa, 2004).   
1.1.3 Mouse models of human CRC 
Over the last two decades, many mouse models have been generated that accurately 
recapitulate aspects of the underlying molecular pathogenesis as well as the cellular and 
tissue distribution of human CRC. Mice harboring individual causative mutations are 
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frequently intercrossed to more closely mimic the accumulation of genetic mutations 
occurring during malignant transformation in human CRC. These mouse models have been 
utilized as an important experimental tool for studying CRC.  
Mouse models for hereditary CRC 
ApcMin. FAP patients, harboring a germ-line mutation in APC, develop hundreds of 
intestinal adenomas.  A nonsense mutation in the orthologous gene in mice is referred to as 
the multiple intestinal neoplasia allele of Apc (ApcMin) (Moser et al., 1990). ApcMin mice 
develop tens to hundreds of intestinal tumors, depending on the mouse strain harboring the 
mutation (Dietrich et al., 1993; Shoemaker et al., 1998). Several genetic modifier loci 
including Mom1 have been identified. These modifiers affect both tumor latency and 
multiplicity (Dietrich et al., 1993; Moser et al., 1992). Despite the fact that FAP patients 
primarily have colonic lesions while the ApcMin mice develop predominantly intestinal 
tumors, the ApcMin mouse model best recapitulates the molecular alternations occurring 
during CRC initiation, thus it is extensively used for testing CRC prevention and therapy. 
Mutations in MMR genes. Germline mutations in the mismatch repair (MMR) 
genes, including MLH1, MSH2, PMS1, and PMS2, cause Lynch syndrome in humans. 
Mice with targeted mutations in each of the known MMR genes have been generated 
(Prolla et al., 1998). Deficiency in MMR genes leads to microsatelite instability in these 
mice. While mice that are haploinsufficient for a MMR gene do not develop noticeable 
phenotypes, nullizygous mice display a reduced life span due to spontaneous 
tumorigenesis usually in lymph nodes, but relatively few in the intestinal tract. These mice, 
however, are genetically susceptible to CRC upon exposure to mutagens like N-methyl-N-
nitrosourea (Qin et al., 2000). MMR deficiency also accelerates intestinal tumorigenesis in 
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ApcMin mice (Reitmair et al., 1996). 
   Mutations in TGFB signaling. Transforming growth factor beta (TGFB), exerts 
growth inhibitory effects in epithelial cells. The TGFB signal acts through the 
TGFB1/TGFB2 serine/threonin receptor complex. A series of related intracellular SMAD 
proteins, SMAD2/3/4, are responsible for transmitting a signal from the activated TGFB 
receptors into nucleus. Mutations in TGFB signaling contribute to both familial and 
sporadic CRC. About 50% of juvenile polyposis, a less common form of hereditary CRC, 
is caused by SMAD4 mutations. Mice lacking Tgfbr2 are embryonically lethal, precluding 
its use to test the role of Tgfbr2 in HNPCC (Oshima et al., 1996). Additionally, mice 
nullizygous for Tgfbr1 die early due to massive multi-organ inflammatory disease 
(Kulkarni et al., 1993; Shull et al., 1992), demonstrating the immuno-regulatory nature of 
TGFB. When Tgfbr1-/- is transferred onto an immuno-deficient Rag2-/- background, the 
compound mutant Tgfbr1-/- Rag2-/- mice live to adulthood and rapidly develop colonic 
carcinoma (Engle et al., 1999).  
The targeted null mutation in Smad4 is embryonic lethal (Sirard et al., 1998). 
However, mice harboring one copy of a targeted null allele of Smad4 do not develop 
intestinal polyps, but do show enhanced tumorigenesis in combination with heterozygosity 
for ApcMin (Takaku et al., 1998). Interestingly, although SMAD3 mutations have not been 
detected in human CRC, mice deficient in Smad3 on a 129Sv/J background display colonic 
cancers similar to late stage human CRC, including adenocarcinoma and metastatic disease 
(Zhu et al., 1998). Moreover, when Smad3-deficient mice are bred to an Apcmin 
background, the compound genetic defects exhibit a synergistic effect on tumorigenesis, 
particularly in the distal part of colon (Sodir et al., 2006). It is of note that the reported 
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carcinomas developed in Smad3 deficient mice are highly influenced by the endogenous 
gut microflora in susceptible strains (Maggio-Price et al., 2006), highlighting the notion 
that inflammation plays an important role in carcinogenesis, especially through TGFB 
signaling. 
  Azoxymethane (AOM) models for sporadic CRC. AOM is a procarcinogen that 
can be metabolized in vivo into a colon-specific carcinogen. Administration of AOM in 
mice produces adenocarcinoma in situ within the colon, mimicking cancer distribution in 
human CRC. More importantly, AOM-induced tumors in mice exhibit remarkable 
similarity in initiation, progression, distribution and histology with sporadic CRC in 
humans (Wang et al., 1998). Also, mutations that occur in sporadic CRC, including Apc, 
Kras2, Tgfb1 and β-catenin, have been detected in AOM-induced tumors (Shivapurkar et 
al., 1994; Vivona et al., 1993). Thus, this model has been used extensively in studying 
sporadic CRC. 
Cross-species and cross-model gene expression comparisons of 100 human 
colorectal cancer samples and 39 colonic tumors from ApcMin, AOM-induced, Smad3-/-, 
Tgfr1-/-Rag2-/- mouse models have revealed the molecular characteristics for each model 
(Kaiser et al., 2007). Unsupervised clustering separated the four mouse models into two 
distinct classes based on their global gene expression patterns: ApcMin and AOM-induced 
vs. Smad3-/-and Tgfr1-/- Rag2-/- tumors. Nuclear β-catenin-positive ApcMin /AOM tumors 
display up-regulation of genes associated with increased canonical WNT signaling. In 
contrast, Smad3-/- and Tgfr1-/- Rag2-/- tumors lack activation of canonical WNT signaling, 
but they exhibit up-regulation of genes associated with inflammatory responses. 
Furthermore, this comprehensive, comparative molecular analysis has revealed that the 
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four mouse models of CRC are similar to human CRC tumors, although ApcMin/AOM are 
more similar than the Smad3-/- and Tgfr1-/- Rag2-/- tumors at a transcriptional level. Thus, 
ApcMin and AOM-induced models are perhaps more relevant to human CRC.  
1.1.4 Management of CRC 
Over the past decade, remarkable progress has been made in the management of 
CRC. Consequently, treatment of CRC has evolved into multi-modality therapeutic 
approaches to both primary and metastatic malignancies. For patients who have resectable 
CRC, surgery is the treatment of choice. However, up to a third of patients have locally 
advanced or metastatic forms of CRC at the time of diagnosis, which precludes a surgical 
cure. Even in patients that undergo apparently curative resection, many still develop 
advanced, non-resectable CRC that requires systemic treatment. The cornerstone of 
systemic treatment for CRC is 5-fluorouracil (5-FU), which was developed in 1957. It is a 
fluorinated pyrimidine that acts primarily through inhibition of thymidylate synthetase, the 
rate-limiting enzyme in pyrimidine nucleotide synthesis. Chemotherapy with 5-FU 
improves median survival from five to 11 months compared to the best supportive care 
(Varadhachary and Hoff, 2005). For the subsequent 40 years, chemotherapy with 5-FU 
was the only option for patients with non-resectable CRC. In the past decade, two 
chemotherapy drugs, irinotecan and oxaliplatin, have been included in the standard care 
regimen for improved survival of patients with metastatic CRC. Irinotecan is a 
topoisomerase I inhibitor, and oxaliplatin is a platinum-based chemotherapy drug. Today, 
the median survival time of patients with CRC has doubled from 10 months with 5-FU 
alone to 20 months with 5-FU plus these newer cytotoxic agents.  
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Despite the improvement using these cytotoxic chemotherapeutic drugs for CRC, 
many patients develop a progressive disease that is resistant to chemotherapy. In these 
‘chemo-refractory’ patients, no effective chemotherapeutic treatment is available. Also, the 
severe chemotherapy-related cytotoxicities, although rare, affect patient’s life quality. 
Fortunately, advances in understanding tumor biology have revolutionized drug design. A 
number of molecule-targeted drugs are now being evaluated in clinical trials and some 
have reached the market. These drugs specifically target altered pathways in tumor cells, 
potentially achieving anti-tumor efficacy with lower toxicity resulting in higher tolerance. 
Examples are therapies targeting the epidermal growth factor receptor (EGFR). Anti-
EGFR therapies have achieved clinical activity in about 10% of patients with metastatic 
CRC that are resistant to chemotherapy (Chong and Cunningham, 2005), with limited 
toxicities. Combinations of newer targeted agents with traditional chemotherapies are 
being evaluated currently in clinical trials. 
1.2 The ERBB family of receptor tyrosine kinases and colorectal cancer 
1.2.1 Introduction to the ERBB family of receptor tyrosine kinases 
The ERBB family of receptor tyrosine kinases consist of four closely related 
members: the epidermal growth factor receptor (EGFR or ERBB1), ERBB2, ERBB3 and 
ERBB4 (Gullick and Srinivasan, 1998) (Figure 1-3A). They are ligand-induced receptor 
tyrosine kinases composed of three essential domains: the extracellular ligand-binding 
domain, a transmembrane domain and a cytoplasmic domain with intrinsic tyrosine kinase 
activity (Wells, 1999) . Activation of ERBB receptors is controlled spatially and 
temporarily by the stimulation of EGF-related ligands, in an autocrine or paracrine manner 
(Beerli and Hynes, 1996). Upon ligand binding, they undergo homo- or heterodimerization 
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(Weiss et al., 1997). The activated receptors recruit and phosphorylate downstream effecter 
proteins activating a cascade of intracellular signaling pathways. Depending on the ligand, 
the receptor dimers formed, the pathways being recruited, and concurrent molecular events 
within the cell, the biological output can regulate many cellular activities including 
proliferation, migration, adhesion, differentiation and survival (Olayioye et al., 2001; 
Salomon et al., 1995) (Figure 1-3B). The activated receptor complexes are endocytosed 
and are either directed to endosomal compartments for degradation (Levkowitz et al., 
1998; Waterman et al., 1998), or recycled back to the cell surface (Waterman et al., 1998).  
The complexity of signaling by ERBB receptors stems from their interdependence 
and complementation. Each receptor has a unique spectrum of ligand specificity. Of the 
four ERBB members, ERBB2 and ERBB3 are functionally non-autonomous: ERBB2 does 
not have a recognized ligand, while ERBB3 lacks intrinsic kinase activity. ERBB2 is a 
preferred binding partner for other ERBBs. The EGFR and ERBB2 heterodimer not only 
displays a reduced internalization rate, prolonged signaling power and biological potency 
(Lenferink et al., 1998), but also has an expanded signal diversity (Graus-Porta et al., 
1997). ERBB3 is the only member in the family that contains multiple PI3K binding sites. 
Once trans-phosphorylated, ERBB3 can bind directly to PI3K and activate the PI3K-AKT 
pathway. Although functionally incomplete on their own, the heterodimer between ERBB2 
and ERBB3 is not only completely functional, but has the most potency of the ERBB 
family with respect to signaling.  
Activated ERBB family members stimulate a variety of intracellular signaling 
pathways, of which the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3-kinase (PI3K)-AKT pathways are of most significance (Yarden and 
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Sliwkowski, 2001). Additionally, the signal transducer and activator of transcription 
(STAT), protein kinase C and phospholipase D pathways (Citri et al., 2003) are also 
important and are known to mediate anti-apoptotic signaling in various cell types (Garcia, 
2001). Examples of important effecter proteins include the intracellular tyrosine kinase 
SRC (Biscardi et al., 1999; Tice et al., 1999) and the mammalian target of rapamycin 
(mTOR), a serine-threonine kinase activated downstream of PI3K-AKT (Bjornsti and 
Houghton, 2004).  
To add another layer of complexity, the ERBB family members are also involved 
in a broader signaling network by active ‘cross-talk’ with other receptor classes. For 
example, the G-protein coupled receptor protein (GPCR) can transactivate EGFR by 
increasing the availability of EGF-related ligands (Carpenter, 2000; Prenzel et al., 1999). 
Another important example is the binding of growth hormone to its receptor can also lead 
to EGFR phosphorylation through Janus tyrosine kinase (JNK) (Yamauchi et al., 1998). 
These examples demonstrate that exposure of cells to non-EGF related peptides can also 
activate EGFR-mediated signaling pathways. 
1.2.2 ERBB family members in intestinal development and homeostasis 
Normal signaling through ERBB family members is essential in almost every tissue 
of the body, including skin, brain, lungs and the GI tract. This ERBB-mediated signaling is 
required during embryonic development and is then used throughout life for the maturation 
and maintenance of most organ systems (Miettinen et al., 1995; Sibilia et al., 1998; 
Threadgill et al., 1995). Among the four ERBB members, EGFR and its cognate ligands 
are most relevant in intestinal development. It has been shown that EGF stimulation leads 
to accelerated lung and intestinal maturation before birth and in newborn animals (Vinter-
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Jensen, 1999). Additionally, it was demonstrated that EGFR hyperstimulation in TGFΑ 
overexpressing transgenic mice (Acra et al., 1998) or injection of EGF in adult mice 
(Dyduch, 1990), leads to increased intestinal epithelial proliferation and an increase in the 
dimension of the crypt/villi unit. Interestingly, although EGFR deficiency in mice caused 
defects in proliferation and differentiation in epithelial compartments of the lungs and the 
skin, no abnormalities were observed in the intestinal epithelium in mutant pups until 
weaning (Sibilia and Wagner, 1995; Threadgill et al., 1995), suggesting the presence of 
compensatory pathways supporting intestinal epithelium development in surviving Egfr-/- 
pups. 
Signaling through EGFR is critical for intestinal adaptation following small bowel 
resection. Elevated post-resection EGFR expression was detected within the crypt and 
muscularis compartments in the small bowel (Knott et al., 2003). EGFR regulates intestinal 
adaptation to resection by mediating enterocyte proliferation, a process that requires 
MAPK-dependent p21Waf1/Cip1 expression (Sheng et al., 2006). In addition, EGFR 
activation prevents resection-induced enterocyte apoptosis by modulating the proapoptotic 
protein BAX in a p38MAPK-dependent manner(Sheng et al., 2007). Consistent with these 
observations, EGF administration in mice, associated with increased EGFR mRNA and 
protein, augments intestinal adaptation following resection (Helmrath et al., 1998). In 
contrast, adaptation following resection is impaired in mice with reduced EGFR kinase 
activity (Helmrath et al., 1997). 
1.2.3 Deregulation of ERBB family member signaling in CRC 
Overexpression of one or more ERBB receptors has been found in the majority of 
carcinomas, with amplification of ERBB2 in 20-30% of metastatic breast cancers. 
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Abnormal activation of the ERBB family members has been documented in many other 
types of human epithelial cancers, including lung, skin, breast, prostate gland, head/neck 
and colorectal cancers. In CRC, the role of EGFR has been extensively studied and EGFR 
has been viewed as an attractive drug target for CRC treatment. Other ERBB family 
members, particularly ERBB2 and ERBB3, have been also implicated in CRC. The role of 
ERBB4 has not yet been elucidated. The advances in understanding of ERBB biology 
together with the growing knowledge of the complex functional interactions among ERBB 
members should allow the design of better ERBB-targeted drugs. 
EGFR  
EGFR over-expression has been detected in 70-80% of metastatic CRC (Messa et 
al., 1998; Porebska et al., 2000). CRC tumors with aberrant EGFR signaling present with 
advanced disease stages and poor prognosis (Mayer et al., 1993). Blocking EGFR in colon 
cancer cell lines achieved anti-tumor activity by inhibiting EGFR-mediated signaling 
pathways including PI3K-AKT, MAPK and SRC, resulting in increased cell cycle arrest, 
decreased proliferation and increased apoptosis (Moyer et al., 1997; Wu et al., 1995; Wu 
et al., 1996). In addition, a synergistic anti-tumor effect was observed when an EGFR 
blockade was combined with the chemotherapeutic agent irinotecan in colon cancer cells 
grown as xenografts in nude mice (Prewett et al., 2002). These combined therapies 
effectively controlled tumor growth and led to extensive tumor necrosis, decreased tumor 
cell proliferation, increased tumor cell apoptosis, and a marked decrease in tumor 
vasculature. These results suggest that an EGFR blockade could overcome cellular 
resistance to irinotecan, and this combined therapy approach might be effective for 
patients with chemo-refractory CRC.  
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ERBB2 
Similar to EGFR, ERBB2 is also frequently overexpressed in CRC when compared 
to normal adjacent colon tissue, though the actual frequency varies with detection 
technology (Gill et al., 2002; Nathason et al., 2003). It also has been demonstrated that 
ERBB2 stimulates proliferation in colon epithelial cells (Nowak et al., 1997); inhibition of 
ERBB2 causes regression of EGFR-dependent cancer cells grown as xenografts in athymic 
mice (Kuwada et al., 2004). A recent study reported somatic mutations in the ERBB2 
kinase domain detected in gastric, breast and colorectal carcinomas from Asian patients 
(Lee et al., 2006). However, anti-ERBB2 therapies have been employed primarily in breast 
cancers, which have the greatest degree of overexpression of ERBB2 compared to other 
common epithelial tumors; few studies have examined the therapeutic potential of ERBB2 
inhibition in CRC. Since EGFR and ERBB2 are preferred heterodimerization partners and 
deliver a strong mitogenic signal, targeting ERBB2 and EGFR simultaneously in colon 
cancers might be a more effective approach than targeting a single receptor. In in vitro 
studies, inhibition of EGFR by small molecule inhibitors led to increased activation of 
ERBB2 in colon cancer cells, suggesting the compensatory regulation within ERBB family 
members in response to EGFR inhibition (Learn et al., 2006). Targeting both the EGFR 
and ERBB2 had additive effects on cell proliferation inhibition, apoptosis induction and 
tumor inhibition, demonstrating a cooperation of EGFR and ERBB2 in colon cancer cells 
(Kuwada et al., 2004). In 2007, the US Food and Drug Administration (FDA) approved the 
dual EGFR/ERBB2 inhibitor lapatinib (Tykerb, GSK) to be used in combination with 
capectabine (Xeloda), for patients with advanced metastatic breast cancer that is ERBB2 
positive. Its efficacy in CRC warrants further study. 
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ERBB3 
Overexpression of ERBB3, often accompanied with EGFR or ERBB2 
overexpression, has been frequently detected in a variety of cancers, including breast 
(Naidu et al., 1998), gastric (Kobayashi et al., 2003), ovarian (Rajkumar et al., 1996), 
pancreatic (Friess et al., 1999) and colorectal cancers (Ciardiello et al., 1991; Maurer et al., 
1998). Indeed, the ERBB3/PI3K/AKT axis contributes to gefitinib sensitivity in NSCLC 
cells (Engelman et al., 2005). Recently, it was demonstrated that ERBB3-dependent 
activation of PI3K/AKT, driven by amplification of the MET proto-oncogene, underlies 
the acquired resistance to gefitinib in a subset of NSCLC patients (Engelman et al., 2007). 
Additionally, ERBB3-dependent signaling, through ERBB2-ERBB3 heterodimers, has 
been shown to contribute to the enhanced invasiveness of mammary tumor cells (Xue et 
al., 2006). Altogether, it has become increasing clear that in cancers driven by EGFR or 
ERBB2 signaling, as seen in breast cancer and NSCLC cells, ERBB3 mainly functions as a 
signaling partner /substrate for EGFR or ERBB2 and mediates resistance to inhibitors of 
EGFR and ERBB2 in cancer cells. To date, little is known about the role of ERBB3 in 
colorectal cancer. 
Cancer research over the past decades has uncovered some of the crucial 
downstream pathways mediated through ERBB family members in CRC cells. In an over-
simplistic way, ERBB signals can be roughly divided into two categories: the pro-
proliferative axis consisting of the RAS-RAF-MEK (mitogen-activated and extracellular 
signal regulated kinase kinase)-MAPK pathway and the pro-survival axis comprising the 
PI3K-mTOR-AKT pathway. Although these pathways are probably controlled by many 
RTK outputs, aberrant signaling in ERBB family members results in alterations in activity 
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of these downstream effecters, accounting for increased proliferation, increased protein 
synthesis and decreased apoptosis in cancer cells.  
1.2.4 Therapeutic targeting of ERBB family members in CRC 
In vivo pharmaceutical studies that target EGFR in the ApcMin mouse model of CRC 
have produced conflicting results. In one study, EGFR inhibition by small molecule kinase 
inhibitors EKI-785 and EKB-569 achieved a significant reduction in polyp number 
(Torrance et al., 2000). In contrast, Ritland et al. observed no effect on polyp number by 
using CFPQA, an irreversible EGFR kinase inhibitor (Ritland et al., 2000). The first 
genetic evidence to confirm the validity of EGFR as a drug target for CRC came from 
ApcMin tumors formed on an Egfrwa2 background (Roberts et al., 2002); the receptor 
encoded by Egfrwa2 has an impaired kinase activity due to a Val743 -> Gly substitution in 
the kinase domain (Luetteke et al., 1994). The reduced EGFR activity caused by the 
Egfrwa2 allele dramatically inhibited tumor multiplicity by up to 90%.  Interestingly, the 
ApcMin tumors that did arise in Egfrwa2 homozygous mice were indistinguishable in size, 
expansion, and pathological progression compared to those tumors arising in mice with 
wildtype activity levels of EGFR, suggesting that some tumors can grow independently of 
EGFR.  
Based on promising preclinical results, EGFR-targeted therapies are now in 
advanced clinical development and several have been licensed to treat cancer patients in 
combination with other therapies (Hynes and Lane, 2005). Indeed, two classes of agents 
targeting EGFR, small molecule tyrosine kinase inhibitors (TKIs) that target the tyrosine 
kinase domain and monoclonal antibodies (mAb) that target the extracellular ligand-
binding domain, have received regulatory approval as cancer treatments. Since the ligand-
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receptor interaction is the first step in initiating further signaling cascades, blocking the 
ligand-binding domain with mAb inhibits ERBB signaling and results in receptor 
internalization. In addition, some mAbs also elicit host immune responses, referred to as 
‘antibody-dependent cell-mediated cytotoxicity’, to kill tumor cells bound with the 
antibody. Alternatively, ERBB TKIs inhibit ERBB kinase activity by binding to the 
intracellular kinase domain and preventing ATP binding.  
Cetuximab (Erbitux, Imclone) was the first chimeric human/mouse IgG1 mAb 
targeting EGFR that received approval from the FDA for patients with metastasized CRC 
who failed to respond to conventional chemotherapy. Subsequently, panitumumab 
(Vectibix, Amgen), a fully human IgG2 anti-EGFR mAb, was approved for patients with 
CRC that progressed following standard chemotherapy. Both cetuximab and panitumumab 
demonstrated a positive effect in about 10% of patients with chemotherapy-refractory 
metastatic CRC (Cunningham et al., 2004; Hecht, 2004; Saltz, 2004). It should be noted 
that although EGFR expression was initially the criteria to select patients who would 
potentially benefit from cetuximab, it was subsequently found not to correlate with patient 
response to the drug. Interestingly, accumulating evidence suggests that the development 
of a skin rash, a common side effect with EGFR mAb, could be a good indicator of 
favorable response and survival (Galizia et al., 2007). However, the molecular mechanisms 
underlying these clinical responses to EGFR-targeted therapy have not been completely 
elucidated. 
As opposed to EGFR mAb, the performance of EGFR TKIs in CRC treatment has 
been less consistent. Gefitinib (Iressa, AstraZeneca), an orally dosed EGFR TKI, was first 
approved for marketing in 2003 to treat NSCLC. Although Gefitinib exhibited anti-tumor 
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activity against human CRC cell lines growing as xenografts (Bianco et al., 2002), large-
scale multinational phase III clinical trials demonstrated no survival benefits when 
gefitinib was used in combination with chemotherapy (Gatzemeier et al., 2004; Giaccone 
et al., 2004; Herbst et al., 2004). However, another reversible TKI, Erlotinib (Tarceva; 
OSI) has demonstrated its efficacy and safety in patients with metastatic CRC in a phase II 
trial (Townsley et al., 2006). Ongoing clinical trials are further evaluating its use as a 
single agent or in combination with conventional chemotherapy in CRC treatment. Due to 
the interdependence within different ERBBs, newer generations of TKIs are being 
developed to target multiple ERBB family members, such as dual- or pan-ERBB 
inhibitors. In particular, lapatinib (Tykerb, GSK), the dual EGFR/ERBB2 inhibitor, has 
been approved for use against ERBB2-positive breast cancers.  
An understanding of the molecular basis for sensitivity or resistance to EGFR 
inhibition would help predict how tumor cells respond to the activities of anti-EGFR 
agents. So far, the presence of somatic mutations in EGFR that may be associated with 
resistance to EGFR-targeted therapy has only been identified in a sub-population of non-
small cell lung cancer patients (Paez et al., 2004; Pao et al., 2004). Moreover, the presence 
of KRAS mutations, arising frequently in smokers, has been linked with resistance to 
EGFR inhibitors in lung cancer patients (Pao et al., 2005). In other types of cancers such as 
CRC, little is known about the molecular mechanisms underlying response to EGFR-
targeted therapies. It is likely that many factors are involved, including a lack of relevance 
of the EGFR signaling pathways to tumor growth, inherent molecular heterogeneity of 
tumors, and/or genetic heterogeneity of patients. Using the ApcMin mouse model of CRC 
and the hypomorphic Egfrwa2 allele, previous studies have shown that a subset of intestinal 
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polyps arise on a background with reduced EGFR activity (Roberts et al., 2002). These 
polyps develop despite a greatly reduced level of active receptor, and the size, expansion, 
and pathological progression of these polyps appear identical to those with wildtype 
EGFR. These results support the concept that CRC can be EGFR independent, i.e. tumors 
do not respond to EGFR inhibition due to lack of relevance of EGFR-mediated signaling 
or compensatory activation of other pathways for tumor growth.  
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Figure 1-1 The colorectal cancer death rates in the United States, 1990 to 2003. 
The source of data is from Jemal et al., 2007.White bar represents Year 1993 and white bar 
represnts Year 2003. 
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Figure 1-2 The molecular pathogenesis of colorectal cancer (adapted from (Kinzler and Vogelstein, 
1996)). 
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Figure 1-3 Conserved molecular structure and signaling cascades of the ERBB family members. 
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Chapter 2 Identification of EGFR-independent signatures in 
ApcMin tumors
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Abstract 
The epidermal growth factor receptor (EGFR) has been intensely pursued as a 
therapeutic target for colorectal cancer (CRC) due to its aberrant activity in tumor tissues. 
However, large-scale clinical trials have achieved limited success, suggesting greater 
complexity of EGFR biology than previous anticipated. Using the ApcMin mouse model of 
CRC, we previously showed that a subset of intestinal polyps arise on a background with 
reduced EGFR activity; the size, expansion, and pathological progression of these polyps 
appear EGFR-independent. Therefore, we hypothesize that although normal EGFR 
signaling is critical for establishment of most intestinal tumors, tumors can grow 
independent of EGFR activity. To test this hypothesis, we generated mice with cre-
mediated intestinal epithelia-specific Egfr deletion. BrdU incorporation studies indicate 
that inactivation of EGFR does not decrease proliferation in the intestinal epithelium. We 
observed a 57.5% reduction in total polyp number in 3-month-old Egfrtm1Dwt/tm1Dwt, Vil-Cre, 
ApcMin mice compared to wild-type Egfr littermates (46.2 ± 25.7, versus 108.8 ± 61.2; p(one-
sided) = 0.006). Interestingly, polyps forming in Egfrtm1Dwt/tm1Dwt, Vil-Cre mice were slightly 
larger than those forming in the controls (1.08 ± 0.57 mm versus 1.04 ± 0.56 mm; p(one-sided) 
= 0.04), suggesting that absence of EGFR signaling does not affect the growth of tumors. 
Microarray gene expression profiles of these EGFR-independent tumors were analyzed by 
Significance Analysis of Microarray software and revealed distinctive molecular features 
that partition tumors based on EGFR status. These signatures are marked by up-regulation 
of components in cell cycle regulations and RAS-MAPK pathway, correlating well with 
dramatic increase in p42/44 MAPK activity and proliferation index seen in EGFR-
independent tumors. Meanwhile, the protein level of ERBB2 and ERBB3 is elevated in 
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these tumors, correlating with increased Akt phosphorylation and impaired caspase-3 
activity. These studies define a subset of tumors that grow independent of EGFR and 
demonstrate that this tumor subtype is likely to be constitutive of EGFR wild type tumors. 
Thus, the identification of molecular characteristics of EGFR-independent tumors provides 
a novel mechanism of tumor resistance to EGFR inhibition, and might help to identify 
which tumors will respond to this therapy and provide compelling rational to explore the 
combinatorial therapies of EGFR inhibitors with another drug that target RAS-MAPK 
pathway. 
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2.1 Introduction 
The epidermal growth factor receptor (EGFR) is the prototypical ligand-induced 
receptor tyrosine kinase (RTK) that belongs to the highly conserved ERBB family (Yarden 
and Sliwkowski, 2001). It was the first RTK to be targeted for anti-cancer therapies (Masui 
et al., 1984; Sato et al., 1983; Zirvi, 1983). Upon ligand binding, EGFR homo- or hetero-
dimerizes with other ERBB family members (Weiss et al., 1997). Activated EGFR then 
initiates a complex signal transduction network, which includes the Ras/mitogen-activated 
protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)-AKT pathways 
among others (Yarden and Sliwkowski, 2001).  
Accumulated evidence implicates the importance of EGFR in the development of 
human epithelial neoplasms (Hynes and Lane, 2005). This receptor was initially found to 
be overexpressed  in squamous cell carcinomas and glioblastomas (Derynck, 1992; 
Libermann et al., 1985). Overexpression or hyperactivation of EGFR has been found to be 
associated with tumor progression and poor prognosis in a variety of epithelial 
malignancies such as lung, breast, head and neck and gastrointestinal tract cancers 
(Salomon et al., 1995; Nicholson et al., 2001; Sharma et al., 2007). Due to these aberrant 
alterations in EGFR-mediated signaling pathways EGFR was proposed as a plausible 
target for selective anti-cancer therapy. Subsequently, numerous EGFR-targeting agents 
have been developed for cancer treatment. These agents have achieved anti-tumor effects 
in cancer cell lines and xenografts in nude mice by inhibiting EGFR phosphorylation and 
down-regulating EGFR-mediated signaling pathways, including PI3K-AKT, MAPK and 
SRC. The down-regulation of these pathways via EGFR inhibition results in increased cell 
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cycle arrest, decreased cell proliferation and increased apoptosis (Moyer et al., 1997; Wu et 
al., 1995; Wu et al., 1996). Due to the promising results from preclinical and early clinical 
trials, two classes of EGFR-targeting agents, small molecule tyrosine kinase inhibitors  that 
target the tyrosine kinase domain and anti-EGFR monoclonal antibodies (mAb) that target 
the extracellular ligand-domain of EGFR, received regulatory approval as cancer 
treatments..However, the large-scale multinational phase III clinical trials demonstrated no 
survival benefits for patients with metastatic colorectal cancer when the TKI gefitinib 
(Iressa, AstraZeneca) were used in combination with chemotherapy (Gatzemeier et al., 
2004; Giaccone et al., 2004; Herbst and Sandler, 2004). In addition, the chimeric IgG1 
antibody cetuximab (Erbitux, IMC-C225; ImClone) and human IgG2 antibody 
panitumumab demonstrated a positive effect in only 10% of patients with chemotherapy-
refractory metastatic CRC (Cunningham et al., 2004; Hecht, 2004; Saltz, 2004). The 
molecular mechanisms underlying these clinical responses to EGFR-targeted therapy have 
not been elucidated.  
An understanding of the molecular basis for sensitivity or resistance to EGFR 
inhibition is essential to improve response rates and to identify those cancers likely to 
respond to anti-EGFR therapies. The presence of somatic mutations in the EGFR 
associated with sensitivity to EGFR-targeted therapies has only been detected in a sub-
population of patients non-small cell lung cancer (PMID: 15118125 and 15118073) (Paez 
et al., 2004; Pao et al., 2004). Moreover, the presence of KrRAS mutations, arising 
frequently in smokers, has been linked with resistance to EGFR inhibitors in lung cancers 
(Pao et al., 2005). In other types of cancers such as CRC, little is known about the 
molecular mechanisms underlying the response to EGFR-targeted therapies. It is likely that 
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many factors including a lack of dependency on the EGFR signaling pathway by CRCs, 
inherent molecular heterogeneity of cancers, and/or genetic heterogeneity of patients are 
involved. Using the ApcMin mouse model of CRC and the hypomorphic Egfrwa2 allele, we 
previously showed that polyp development is greatly reduced, but that a subset of intestinal 
polyps still arise on a background with reduced EGFR activity (Roberts et al., 2002; 
Torrance et al., 2000). The growth and pathological progression of polyps with impaired 
EGFR signaling appear identical to those with wild-type levels of EGFR. These results 
suggest that CRCs can arise independently of EGFR.  
To test the hypothesis that tumors can grow independently of EGFR, we generated 
ApcMin mice specifically lacking EGFR in the intestinal epithelium using a conditional Egfr 
allele (Egfrtm1Dwt). In the present study, we demonstrate that ApcMin mice deficient for 
EGFR in the intestinal epithelium have an equivalent reduction in the number of intestinal 
adenomas as observed with the Egfrwa2 allele on the ApcMin background. Similarly, the size 
of the tumors that grow in the absence of EGFR is not impaired. Using these genetically 
distinct tumors, we show that tumors have an EGFR-dependent gene expression signature 
that reflects the activation status of compensatory pathways regulating cell proliferation 
and apoptosis. Our results define a subset of tumors that grow independently of EGFR and 
a putative biomarker for response to EGFR inhibitor therapy.  
2.2 Materials and Methods 
Mice. C57BL/6J (B6)- ApcMin mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). Cre transgenic mice, B6;D2-Tg(Vil-cre)20Syr (MMHCC, 01XE7) were 
obtained from NCI-Frederick and maintained on C57BL/6J background as hemizygous. 
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Mice were fed Purina Mills Lab Diet 5058 under specific-pathogen-free conditions in an 
American Association for the Accreditation of Lab Animal Care–approved facility. Mice 
were euthanized by CO2 asphyxiation for tissue collection.  
Genotyping. Mice were genotyped for the ApcMin allele as previously described (Roberts 
RB et al., 2002). Cre transgenic mice were determined using PCR with cre-S1, 5'-
gtgatgaggttcgcaagaac-3' and cre-AS1, 5'-agcattgctgtcacttggtc-3' primers which brings a 
278-bp PCR product. Mice were genotyped for the Egfrtm1Dmt allele as previously described 
(Lee et al., 2007). 
Tissue collection. The small intestine and colon were removed from each mouse. The 
small intestine was cut into thirds. Each segment were gently flushed with PBS to remove 
fecal material, cut longitudinally, and splayed flat. Representative tumors were scored 
before cutting in half under the dissecting microscope. One half were used for RNA 
extraction and array experiment; another half were fixed in 10% neutral buffered formalin 
at 4 °C overnight for histological analysis, or snap-frozen for use in cryo-sectioning. 
Macroadenoma counts. The tumor number and diameter were obtained for the entire 
length of the small intestine and colon, with a dissecting microscope and in-scope 
micrometer at 5x magnification. The smallest tumors that can be counted are 
approximately 0.3 mm in diameter. Tumor scoring was performed without knowledge of 
genotype by the investigator. Changes in tumor growth rate were recorded grossly as 
tumor size. In addition to tumor size, tumors were carefully scored based on number and 
location along the gastro-intestinal (GI) tract. 
Histology and Immunohistochemistry: Intestinal tissues or colon samples were rolled 
into a jellyroll before fixing in 10% neutral buffered formalin. The processed tissues were 
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embedded in paraffin and sectioned (7 µm). Every 50 µm, sections were taken and stained 
with H&E.  
Immunohistochemical procedures were performed as described (Park et al., 2005). 
Colon tumors were rapidly dissected, fixed in 4% paraformaldehyde, and embedded in 
paraffin before cutting ten µm thick sections.  Antigen-retrieval was performed by boiling 
for 20 min in citrate buffer, pH 6.0.  Sections were treated with 0.3% hydrogen peroxide in 
PBS for 30 min, washed in PBS, blocked in PBS plus 3% goat serum and 0.1% Triton X-
100, and then incubated with primary antibodies and HRP-conjugated goat anti-rabbit 
secondary antibody (Sigma, St. Louis, MO). Antigen-antibody complexes were detected 
with DAB peroxidase substrate kit (Vector Laboratories, Burlingame, CA) according to the 
manufacturer’s protocol.   
Microarray experiments. Total RNA was isolated from individual tumors or normal 
epithelial tissue using Trizol (Invitrogen) according to the manufacturer's protocol. Isolated 
RNA was quantified using OD260 nm measurements in a DU 800 spectrophotometer 
(Beckman Coulter). RNA sample integrity and concentration was verified using the RNA 
Nano 6000 Chip Assay on a BioAnalyzer 2100 (Agilent). 
RNA labeling was carried out using the Low RNA Input Fluorescent Linear 
Amplification Kit (Agilent). Two hundred and fifty nanograms of RNA isolated from cell 
lines or 250 ng reference RNA was incubated with 0.7 µL T7 promoter primer at 65°C for 
10 min. For the mouse arrays, a total RNA reference pool isolated from C57BL/6J 
embryos was used. The reactions were incubated on ice for 5 min. cDNA was synthesized 
using 5 × First Strand Buffer, 0.1 M dithiothreitol, dNTP mix, RNase OUT, and MMLV-
RT at 40°C for 120 min and the reaction stopped at 65°C for 15 min. The reactions were 
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placed on ice for 5 min, tap spun, and 1mM of cyanine 3-CTP or cyanine 5-CTP (Perkin 
Elmer) was added to the reactions for the reference and cell lines, respectively. Fluorescent 
cRNA was synthesized using 4 × transcription buffer, 0.1 M dithiothreitol, NTP mix, 50% 
PEG, RNase OUT, inorganic pyrophosphatase, and T7 RNA polymerase at 40°C for 120 
min. The labeled cRNA was purified using an RNeasy Kit (Qiagen). cRNA was quantified 
using a DU 800 spectrophotometer (Beckman-Coulter), and 1 µg of labeled reference and 
1 µg of labeled sample were combined with 30 µL control target solution, 9 µL 25 × 
fragmentation buffer, and 225 µL 2 × hybridization buffer before loading onto 
hybridization chambers containing the appropriate microarray. Agilent 21K mouse oligo 
arrays (Agilent) were used for tumor and normal tissue samples. The slides were incubated 
in a Rotisserie hybridization oven at 60°C for 17 h before the microarrays were washed 
and scanned using a microarray scanner (Agilent). 
Data analysis. Data from the microarrays were extracted using Feature Extraction 
Software (Agilent) and uploaded into GeneSpring (Agilent). The data were normalized 
first by Lowess and then centered around the 'untreated' samples before filtering using the 
default minimum expression level of 0.1. Filtered gene lists were exported for statistical 
analysis using Significance Analysis of Microarrays (SAM) software (Stanford). Lists of 
differentially expressed genes for each tumor genotype were generated using a two-class 
unpaired comparison at a false discovery rate (FDR) of 5 %.  
Quantitative real time PCR (qRT-PCR). Genes with significant changes in expression 
between wa2 tumors and wt tumors, based on ANOVA analysis, were confirmed by qRT-
PCR. cDNA were synthesized from total RNA from each tumor using the High Capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, CA). PCR reactions were set up in 
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96-well MicroAmp Reaction Plates (Applied Biosystems), using cDNA template in 
Taqman Universal PCR Master Mix and 6-FAM labeled primer-probe sets for genes of 
interest (Applied Biosystems). Reactions were run on a Strategene MX3000P machine 
with analysis software. Threshold cycles (Ct) for each target gene will be determined by an 
in-program algorithm, assigning a fluorescence baseline based on readings prior to 
exponential amplification. Analysis of relative gene expression data will be calculated 
using the ∆∆Ct method (Livak and Schmittgen, 2001), with appropriate endogenous 
controls.  
Western blotting. An extract of harvested tissues was prepared by homogenization in 10 
volumes (10 ml/g) of homogenization buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 
0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml of leupeptin, 1 µg/ml of 
aprotinin). The concentration of cleared lysate was measured by Bradford assay (Biorad) 
and equal amounts of protein lysate were loaded onto a 6% acrylamide gel, 
electrophoresed, and transferred to a polyvinylidenedifluoride membrane (Bio-Rad). The 
membrane was incubated in blocking solution containing 5% nonfat dried milk in TBST 
(10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.05% Tween 20) for 1 h at room temperature 
and subsequently incubated with anti (Transduction Laboratories), anti EGFR #1001 
(Santa Cruz), anti phosphorylated p42/44 MAPK and anti phosphorylated Akt (cell 
signaling technology) and anti Akt antibody (Cell signaling) per ml in TBS (10 mM Tris-
HCl [pH 7.4], 150 mM NaCl) at 4°C overnight. Following incubation with primary 
antibody, the membrane was washed four times in TBST and then incubated in blocking 
solution containing goat anti-rabbit immunoglobulin conjugated with horseradish 
peroxidase for 1 hr at room temperature. The membrane was further washed four times in 
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TBST, and specific protein complexes were visualized with the enhanced 
chemiluminescence system (Amersham-Pharmacia). 
Statistics. The nonparametric Mann–Whitney U test was used to analyze tumor data. 
Student t test was used to analyze other comparisons. One-sided P values are given. 
2.3 Results 
2.3.1 EGFR is dispensable for normal proliferation and histological 
organization of the intestinal epithelium. 
A constitutional deletion of Egfr results is pre- or post-natal lethality in mice 
depending upon the strain (Sibilia and Wagner, 1995; Threadgill et al., 1995; Strunk  et al., 
2004). To overcome this limitation, a conditional knockout allele for Egfr was generated 
(Egfrtm1Dwt) by flanking exon 3 with loxP sites (Lee T-C, manuscript in preparation). This 
allele was used to generate mice with the Egfr gene exclusively deleted in the intestinal 
epithelium by crossing Egfrtm1Dwt mice with mice carrying Tg(Vil-Cre)20Syr that expresses 
CRE from the Villin promoter in the small intestine and colon. The resulting Vil-Cre, 
Egfrtm1Dwt mice did not exhibit overt phenotypes when compared to their Egfr wildtype 
littermates (Figure 2-1A). Moreover, these mice displayed a normal epithelium structure 
(data not shown).  
To evaluate the requirement of EGFR signaling for proliferation of the intestinal 
epithelium, proliferating cells were analyzed using BrdU incorporation at three months of 
age. Unexpectedly, Vil-Cre, Egfrtm1Dwt mice had a slight increase in the number of BrdU-
positive nuclei when compared to their Egfr wildtype littermates, although this difference 
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was not statistically significant (Figure 2-1B). These results show that deletion of Egfr in 
this intestinal epithelium does not affect basal cell proliferation rates.  
2.3.2 Intestinal adenoma in the ApcMin model can arise independently of 
EGFR activity 
Using the ApcMin mouse model of human colorectal cancer, we and others 
previously showed that a subset of intestinal polyps arise in the context of reduced or 
pharmacologically inhibited EGFR activity (Roberts et al., 2002; Torrance et al., 2000): 
the size, growth and pathological progression of polyps with reduced EGFR activity may 
be due to stochastic variation in residual EGFR activity or may be EGFR-independent.  To 
distinguish these possibilities, we generated ApcMin mice with intestinal epithelium 
deficient for EGFR (Figure 2-2A). 
At three months of age, tissue-specific deletion of EGFR (Vil-Cre, Egfrtm1Dwt, 
ApcMin) displayed a 57.5% reduction in total polyp number compared to Egfr wildtype 
littermates (46.2 ± 25.7, versus 108.8 ± 61.2; P(one-sided) = 0.006) (Figure 2-2B). This 
EGFR-dependent reduction in the number of small intestinal polyps was observed in the 
proximal and middle regions of small intestine (Figure 2-2C). No difference was observed 
in polyp number between Vil-Cre, Egfrtm1Dwt/+ and Egfr+/+ mice. Similar to the original 
Egfrwa2 studies, the size of polyps that developed in Vil-Cre, Egfrtm1Dwt mice were not 
smaller than those in wildtype Egfr mice, and were even slightly larger than polyps that 
developed in corresponding littermate controls (1.08 ± 0.57 mm versus 1.04 ± 0.56 mm; 
P(one-sided) = 0.04) mirroring the slight elevation in basal epithelium rates in the absence of 
EGFR (Figure 2-2D). Additionally, histological analysis of polyps from Vil-Cre, 
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Egfrtm1Dwt, ApcMin and Egfr+, ApcMin mice did not reveal any difference in morphology or 
pathological progression (data not shown).  
To confirm that the Egfrtm1Dwt allele underwent CRE-mediated recombination in 
polyps derived from intestinal epithelium of Vil-Cre, Egfrtm1Dwt, ApcMin mice, DNA was 
isolated from epithelial cells that had been dissected from individual polyps by laser-
capture-microdissection (LCM). PCR genotyping confirmed that only the recombined 
Egfrtm1Dwt allele (EgfrΔ) was detectable in individual ApcMin polyps from Vil-Cre, Egfrtm1Dwt 
mice (Figure 2-2E). The EgfrΔ allele is functionally null, since western blot analysis 
showed that tumors from Vil-Cre, Egfrtm1Dwt, ApcMin mice produce no detectable EGFR 
protein (Figure 2-2F), while a normal 170 kD EGFR protein can be detected in 
corresponding Egfr wildtype control tumors. 
2.3.3 EGFR-independent tumors have a distinct gene expression signature  
To determine whether EGFR-independent tumors have a distinct gene expression 
signature, we analyzed RNA from epithelia from wildtype mice, tumors from ApcMin mice 
with wildtype Egfr, and tumors from ApcMin mice with either reduced EGFR activity 
(Egfrwa2) or deficient for EGFR (Vil-Cre, Egfrtm1Dwt). Normalization of the data to the 
average of the wildtype, non- ApcMin epithelial samples yielded 17,990 differentially 
expressed genes. Hierarchical clustering with the 17,990 genes using a correlation-based 
centroid-linkage algorithm demonstrated a significant distinction between tumors and 
normal epithelial tissue (Figure 2-3A). Interestingly, tumors with wildtype Egfr were 
highly heterogeneous in their global gene expression patterns and did not cluster by Egfr 
genotype.  
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Significance Analysis of Microarray (SAM) was used to identify differences 
between Egfr wildtype and mutant/deficient ApcMin tumors. This analysis revealed that 103 
genes display statistically significant changes in their mean expression level based upon 
Egfr genotype, with a false discovery rate of 10%.  Hierarchical clustering of the 103 genes 
partitioned the tumors samples into two primary groups, those with wildtype Egfr and 
those that are deficient or mutant for Egfr (Figure 2-3B).  
Based on the SAM analysis, the top genes out of these 103 genes that were 
differentially expressed based upon Egfr genotype were also subjected to hierarchical 
clustering (Figure 2-3C). Interestingly, three genes in the RAS-MAPK pathways (Arhgap4, 
Arhgef1, Map4k2) were significantly upregulated in EGFR-independent tumors, 
suggesting that these tumors have elevated levels of components in RAS-MAPK pathway, 
potentially compensating for the loss of the upstream EGFR signal. Additionally, genes 
that are known to play an important role in cell cycle progression (E2f2, Ccnd3 and Cdc6) 
show higher levels of expression in EGFR-deficient tumors. 
2.3.4 EGFR-independent tumors increased MAPK activity and proliferation 
To confirm the gene expression profiling results, the activity of p42/44 MAPK was 
evaluated by immunohistochemistry (IHC). Tumors from ApcMin mice labeled with the 
anti-p42/44 MAPK antibody displayed p42/44 MAPK immuno-reactivity in the nucleus 
and cytoplasm of adenomas as well as the proliferative compartment of normal crypts. In 
tumors from Egfr+, ApcMin mice, the p42/44 MAPK immuno-reactivity was limited to a 
few cells localized within the tumor (Figure 2-4 A-B).  In contrast, tumors from the Vil-
Cre, Egfrtm1Dwt, ApcMin mice showed strong p42/44 MAPK immunoreactivity throughout 
the tumor (Figure 2-4 C-D). In agreement with the increase in p42/44 MAPK activity by 
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IHC, the proliferation index quantified by Ki67 IHC showed that the numbers of 
proliferating cells were significantly increased in tumors in Vil-Cre, Egfrtm1Dwt, ApcMin mice 
(Figure 2-5 A-E), consistent with basal differences in proliferation measured by analysis of 
BrdU incorporation.  
2.3.5 Reorganization in ERBB family function and elevated anti-apoptotic 
signaling in EGFR-independent tumors  
To investigate whether lack of EGFR in tumors would lead to altered protein level 
of other ERBB family members such as ERBB2 and ERBB3, western blot analysis was 
performed on protein samples extracted from individual tumors from the Vil-Cre, 
Egfrtm1Dwt, ApcMin mice and littermate controls (Figure 2-6). Whereas no detectable EGFR 
protein was present in tumors from the Vil-Cre, Egfrtm1Dwt, ApcMin mice, the protein level of 
ERBB2 and ERBB3 was elevated compared to tumors from EGFR wildtype control mice. 
The AKT-kinase is known to lie downstream of ERBB3 and regulates an anti-apoptotic 
pathway in epithelial cells (Song et al., 2005). Activation of AKT-kinase as detected by 
phospho-AKT antibody was increased in EGFR-deficient tumors. Consequently, activity 
of caspase-3, a critical executioner of apoptosis, was dramatically decreased in EGFR-
deficient tumors as detected by cleaved caspase-3 antibody. These results indicate that 
absence of EGFR results in elevated ERBB2 and ERBB3 protein levels, which may 
contribute to the increased phospho-AKT level and decreased caspase-3 activity. 
2.3.6 EGFR ligands show elevated expression in EGFR-independent tumors 
To investigate the dynamics in expression of EGFR ligands in EGFR-independent 
tumors, real-time PCR analysis was performed on tumors with different Egfr genotypes. 
Tumors lacking EGFR showed an overall elevation in EGFR ligand mRNA level (Figure 
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2-7). In particular, the Ereg (epiregulin), Epgn (epigen), and Tgfa (transforming growth 
factor-alpha) were expressed at significantly higher levels in tumors from Vil-Cre, 
Egfrtm1Dwt, ApcMin mice than those with wildtype Egfr, whereas Btc (betacellulin), Egf 
(epidermal growth factor), Dtr (diphtheria toxin receptor/heparin-binding Egf), Areg 
(amphiregulin) were expressed at levels similar to those in the wildtype Egfr tumors.  
2.4 Discussion 
The fact that majority of colon cancer patients do not respond to anti-EGFR 
therapeutics, despite promising pre-clinical data, is a major hindrance to the success of 
these agents.  Previous reports using genetic and pharmacological inhibition to reduce but 
not eliminate EGFR activity were inconclusive as to whether colon tumors can arise and 
grow independently of EGFR activity since the studies could not distinguish EGFR-
independence from variable residual EGFR activity. In the current studies, we took 
advantage of a conditional knockout allele of Egfr to prove that a subset of colon tumors 
does arise independently of EGFR signaling. Our genetic approach demonstrates that 
despite having far fewer polyps than ApcMin mice with a widetype Egfr, ApcMin mice with 
intestinal-epithelia specific Egfr deletion do develop polyps and these polyps grow in an 
EGFR-independent manner. The absence of EGFR in these polyps exerts little or no 
suppression on their growth and may even enhance tumor growth. Therefore, some tumors 
are likely not to respond to EGFR inhibition since they do not rely on EGFR for survival or 
proliferation. In contrast, targeting EGFR would be most effective for those cancers that 
are dependent upon EGFR signaling. Although mechanistically different, diffferential 
response to EGFR inhibition is well documented in NSCLC where patients harboring 
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EGFR activating mutations exhibit dramatic clinical responses to Gefitinib (Lynch et al., 
2004; Paez et al., 2004; Pao et al., 2004).  
EGFR-independent polyps must rely on alternative signaling pathways for their 
growth and survival. However, given the diversity and complexity of the EGFR signaling 
network, it is not likely that the level of EGFR expression itself is an appropriate marker 
for EGFR-independence. More likely, a host of molecular alterations contribute to growth 
in the absence of EGFR, including changes in the level of activating ligands, ERBB family 
members or effectors of downstream signaling cascades. To generate a molecular 
biomarker for EGFR-status, we utilized global gene expression analysis. Although less 
targeted, expression profiling can identify at the transcriptional level differences in gene 
expression associated with EGFR-status and potentially identify compensatory pathways 
responsible for EGFR-independent tumor growth.  When expression profiles from ApcMin 
tumors with epithelial deletion of Egfr were compared by hierarchical clustering with those 
tumors containing wildtype Egfr, two out of seven Egfr wildtype tumors clustered among 
the tumors with epithelial deletion of EGFR. One explanation for this result is that a subset 
of tumors in the Egfr wildtype tumor population share more similarity in global gene 
expression patterns with Egfr mutant tumors because the EGFR status is constitutional and 
present before selection by loss or inhibition of EGFR. Subsequently SAM was used to 
identify a list of genes that show statistically significant differential gene expression 
between EGFR-dependent and independent tumors. Among the top upregulated genes 
were E2f2, Ccnd3 and Cdc6, important positive regulators of cell cycle progression. Of 
particular interest is that several components in the RAS-MAPK pathway were upregulated 
in the EGFR-independent tumors, including Arhgap4, Map4k2 and Arhgef1. IHC analysis 
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revealed a dramatic increase in p42/44 MAPK activity in EGFR-independent tumors, 
supporting functional upregulation of the MAPK pathway. Consistent with activation of 
the MAPK proliferation pathway, the level of Ki-67 staining was elevated indicating a 
higher proliferation index in the Egfr mutant tumors. This observation was also consistent 
with the fact that EGFR-independnet tumors are slightly larger than those with normal 
EGFR activity. Taken together, the discovery of elevated RAS-MAPK pathway 
components and MAPK activity suggests that an alternative transmembrane signal 
compensates for loss of EGFR in EGFR-independent tumors.  Constitutive activation of 
RAS/MAPK is proposed to be the molecular basis for acquired resistance to gefitinib in 
ERBB2-overexpressing human gastric cancer cell lines derived from liver metastasis  
(Yokoyama et al., 2006). Another recent study in metastatic CRC patients has shown that 
patients with dysregulated MAPK pathway, via an activating Kras mutation, are more 
resistant to Cetuximab treatment (Khambata-Ford et al., 2007).  
Considering that activating Kras mutations have not been reported in ApcMin tumors 
and the intimate cross-talk within EGFR/ERBB family members, it remains to be 
determined what the up-stream transmembrane signal is that compensates for loss of 
EGFR and activation of the downstream MAPK pathway. The elevated protein level of 
ERBB2 and ERBB3 in EGFR-independent tumors strongly indicates that the ERBB2/3 
heterodimer may mediate compensatory pathways. Indeed, the ERBB2/3 heterodimer 
could also contribute to EGFR-independent tumor growth by mediating pro-survival 
signals, as phospho-AKT level is increased in EGFR-independent tumors while the 
caspase-3 activity is dramatically impaired. Consistent with this notion, ERBB3 has been 
shown to mediate sensitivity to EGFR inhibition in pancreatic and colorectal cancer cells 
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(Buck et al., 2006). Our findings may have important clinical implications for CRC 
patients who do not respond to EGFR-targeted therapies. Out results suggest that EGFR 
inhibition, either by small molecular inhibitors or by monoclonal antibodies, may be 
ineffective in the subset of EGFR-independent tumors that exhibit activation of the MAPK 
pathway. Also, ERBB3 could be used as a biomarker to predict clinical responsiveness of 
patients to anti-EGFR therapy. Furthermore, combining inhibitors to important 
downstream effecters such as MAPK or AKT with anti-EGFR therapeutics should be 
considered to achieve better efficacy. 
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Figure 2-1 Inactivation of Egfr in the intestinal epithelium does not decrease the proliferation of the 
epithelial cells. 
A 
B 
control test 
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Figure 2-1. Inactivation of Egfr in the intestinal epithelium does not decrease the 
proliferation of the epithelial cells. (A) An example of a three-month-old Vil-cre, Egfrtm1Dwt 
mouse showing no overt phenotypes compared to its control littermate. Control: Egfr+ 
mouse; test: Vil-cre, Egfrtm1Dwt mouse (B) The number of BrdU positive cells/crypt does 
not alter in the small and large intestines of three-month-old Vil-cre, Egfrtm1Dwt mice 
compared to its control littermate. The black bar represents the control animals; the white 
bar represents the Vil-cre, Egfrtm1Dwt mice. D: duodenum; J: jejum; I: iliem; C: colon. Error 
bar: ± SD. 
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Figure 2-2 EGFR-independent intestinal adenoma growth in ApcMin mice  
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Figure 2-2. EGFR-independent intestinal adenoma growth in ApcMin mice. A. Breeding 
scheme used to generate intestine epithelia-specific Egfr deletion in ApcMin mice. (B) 
Macroadenoma multiplicity in ApcMin mice of different Egfr genotype. Each dot represents 
the polyp number in each 3-month-old mice, (nwt=14, ndeficient=10). (C) The reduction of 
multiplicity along the small intestinal tract. (D) Macroadenoma size in ApcMin mice of 
different Egfr genotype.  Each point in represents the size of individual polyps. (E) PCR 
genotyping of representative ApcMin tumors. PCR amplicons display the generation of the 
EgfrΔ allele in tumors by Villin-cre-mediated excision of Egfrtm1Dwt. The sizes of the PCR 
products for the EgfrΔ, Egfr+ and Egfrtm1Dwt alleles are 234 bp, 800 bp and 1024 bp, 
respectively. M, 1-kb DNA ladder (F) Western blot analysis of EGFR protein levels in 
individual tumors of different genotypes. * p < 0.05; ** p < 0.01; *** p < 0.001, Mann-
Whitney U test 
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 IL2-inducible T-cell kinase (Itk),  [NM_010583] 0.0
 lectin, mannose-binding 2 (Lman2),  [NM_025828] 6.7
 Rho GTPase activating protein 4 (Arhgap4),  [NM_138630] 6.7
 2'-5' oligoadenylate synthetase 2 (Oas2),  [NM_145227] 6.7
 E2F transcription factor 2 (E2f2),  [NM_177733] 6.7
 kallikrein 9 (Klk9),  [NM_010116] 6.7
 kallikrein 21 (Klk21),  [NM_010642] 9.2
 nephronectin (Npnt),  [NM_033525] 0.0
 phytanoyl-CoA hydroxylase interacting protein (Phyhip),  [NM_145981] 0.0
 protein tyrosine phosphatase, receptor type, N polypeptide 2 (Ptprn2),  [NM_011215] 9.2
 protein tyrosine phosphatase, non-receptor type 14 (Ptpn14),  [NM_008976] 9.2
 SWI/SNF related,,  [NM_011416] 6.7
 Atpase, class VI, type 11C (Atp11c),  [NM_001001798] 6.7
 stress-induced phosphoprotein 1 (Stip1),  [NM_016737] 6.7
 cell division cycle 6 homolog (S. cerevisiae) (Cdc6), transcript variant 1,  [NM_011799] 9.2
 mitogen activated protein kinase kinase kinase kinase 2 (Map4k2),  [NM_009006] 6.7
 Rho guanine nucleotide exchange factor (GEF) 1 (Arhgef1),  [NM_008488] 6.7
 cyclin D3 (Ccnd3),  [NM_007632] 9.2
 nicalin homolog (zebrafish) (Ncln),  [NM_134009] 6.7
 FSHD region gene 1 (Frg1),  [NM_013522] 6.7
 dishevelled associated activator of morphogenesis 2 (Daam2),  [NM_001008231] 10.1
 yippee-like 5 (Drosophila) (Ypel5),  [NM_027166] 10.1
 cytochrome P450, family 2, subfamily c, polypeptide 55 (Cyp2c55),  [NM_028089] 10.1
 RIKEN cDNA 2410005O16 gene (2410005O16Rik),  [NM_025476] 10.1
 leptin receptor overlapping transcript-like 1 (Leprotl1),  [NM_026609] 10.1
 adult male testis cDNA, RIKEN full-length enriched library, clone:4930423F13 10.1
 chemokine binding protein 2 (Ccbp2),  [NM_021609] 10.1
 adult male small intestine cDNA, clone:2010208A07 product 10.1
 8 days embryo whole body cDNA,  clone:5730507C01 product 10.1
 chemokine (C-C motif) receptor 1-like 1 (Ccr1l1),  [NM_007718] 10.1
 RIKEN cDNA 4833405L16 gene (4833405L16Rik),  [NM_177197] 10.1
 retinaldehyde binding protein 1 (Rlbp1),  [NM_020599] 10.1
 RIKEN cDNA 4933417K05 gene (4933417K05Rik),  [NM_175488] 10.1
 chemokine (C-X-C motif) ligand 7 (Cxcl7),  [NM_023785] 10.1
PREDICTED:  stefin A2 (Stfa2),  [XM_487424] 10.1
 stefin A1 (Stfa1),  [NM_001001332] 10.1
PREDICTED: filamin A interacting protein 1 [],  sequence [XM_486240] 10.1
PREDICTED:  similar to rbm3 (LOC433432),  [XM_485004] 10.1
PREDICTED: similar to KIAA1917 protein [],  sequence [XM_126776] 10.1
 expressed sequence AI851790 (AI851790),  [NM_182807] 10.1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3 Hierarchical clustering of gene expression patterns from ApcMin tumors 
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Figure 2-3. Hierarchical clustering of gene expression patterns from ApcMin tumors. A. 
Global gene expression patterns analyzed by clustering 17,990 transcripts. Hierarchical 
clustering of (B) the 103 genes identified by SAM that are differentially expressed between 
Egfr mutant and Egfr wildtype tumors and (C) the 40 most differentially expressed genes. 
Blue block (N): samples of intestinal epithelia from EGFR wildtype mice; green block (T-
IND): samples of EGFR-independent intestinal tumors; grey block (T-D): samples of 
EGFR-dependent intestinal tumors. 
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Figure 2-4 IHC analysis of MAPK activity in EGFR-independent ApcMin tumors 
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Figure 2-4 IHC analysis of MAPK activity in EGFR-independent ApcMin tumors. 
Representative immunoreactivity of phospho-42/44 MAPK of ApcMin adenomas with 
wildtype Egfr at (A) 100x and (B) 400x showing variable staining. Polyps from Villin-cre, 
Egfrtm1Dwt, ApcMin mice display an increased level of phospho 42/44 MAPK 
immunoreactivity at (C) 100x and (D) 400x.   
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Figure 2-5 Analysis of proliferation index in EGFR-independent ApcMin tumors 
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Figure 2-5 Analysis of proliferation index in EGFR-independent ApcMin tumors. Anti-Ki67 
immunofluorescence (green) in a representative polyp section from a 3-month-old Villin-
cre, Egfrtm1Dwt, Apcmin (A) and Egfr wildtype control (B) mice.  DAPI (blue) was used for 
nuclear contrast (C-D). 200x magnification. E. Quantification of proliferation index. *, P 
< 0.05, student t test. 
 55 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6 Reorganization in ERBB family function and elevated anti-apoptotic signaling in EGFR-
independent tumors. 
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Figure 2-6 Reorganization in ERBB family function and elevated anti-apoptotic signaling 
in EGFR-independent tumors. Representative western blots showing level of total EGFR, 
total ERBB2 and ERBB3, phospho-AKT, cleaved caspase3 and loading control of two 
individual EGFR wildtype and EGFR-independent tumors.  
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Figure 2-7 EGFR ligands gene expression in EGFR-independent ApcMin tumors 
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Figure 2-7 EGFR ligands gene expression in EGFR-independent ApcMin tumors. 
Quantitative real time PCR analysis of the expression of EGFR ligands amphiregulin 
(Areg), epigen (Epgn), epiregulin (Ereg), betacellulin (Btc), diphtheria toxin receptor (Dtr), 
epidermal growth factor (Egf) and transforming growth factor-alpha (Tgfa). Bars, SE. 
Significantly different gene expression in Egfr mutant versus Egfr wildtype tumors.**= P 
< 0.001; *= P < 0.05, student t test. Black bar: Egfr+ ApcMin tumors; grey bar: EGFR- 
independent ApcMin tumors 
 
Chapter 3 The importance of ERBB3 signaling during intestinal 
tumorigenesis  
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Abstract 
The role of ERBB3 during intestinal tumorigenesis has been under-appreciated, 
probably due to its defective kinase activity. In this study, we generated mice with CRE-
mediated intestinal epithelia-specific Erbb3 deletion to examine the impact of ERBB 
deficiency on the ApcMin mouse model of Familial Adenomatous Polyposis (FAP). We 
observed a 88.5% reduction in total polyp number in 3-month-old ApcMin, Vil-Cre, Erbb3floxΔ 
mice compared to wild-type Erbb3 littermates (10.6 ± 6.8, versus 91.9 ± 76.0; p(one-sided) < 
0.00001). Perhaps more importantly, polyps forming in Vil-Cre, Erbb3floxΔ mice were 
significantly smaller than those forming in the controls (0.62 ± 0.48 mm versus 0.94 ± 0.45 
mm; p(one-sided) < 0.0001), suggesting that normal levels of ERBB3 signaling is essential for 
tumor growth in ApcMin mice. While the proliferation rate as measured by Ki67 staining in 
ERBB3-deficient polyps was comparable to polyps with wild-type ERBB3, an increase in 
TUNEL-positive cells were observed in polyps from ApcMin, Vil-Cre, Erbb3floxΔ mice, 
indicating that ERBB3-dependent signaling prevents apoptosis in ApcMin polyps. 
Consistently, the ERBB3-deficient polyps display reduced immunoreactivity for 
phosphorylation of S6, a downstream mediator of the PI3K/AKT/mTOR pathway, but the 
phosphorylation level of p42/44 MAPK was comparable to polyps with wildtype ERBB3 
activity. In azoxymethane (AOM) model of sporadic colorectal cancer, a significant decrease 
in tumor susceptibility was observed in ERBB3-deficient mice (p(one-sided) < 0.05), compared 
to the wild-type ERBB3 controls. However, there was no difference in the size of AOM-
induced colonic tumors between two groups (3.65 ± 1.6 vs. 3.58 ± 1.1; p = 0.92). These 
results suggest that ERBB3 also contributes to colonic tumors induced by the carcinogen 
AOM, but probably through a different mechanism depending on tumor location. Taken 
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together, this study reveals the importance of ERBB3-mediated PI3K/AKT/mTOR in 
intestinal tumorigenesis, thus provides a valuable target for therapeutic intervention.  
3.1 Introduction 
ERBB3 belongs to the ERBB family of receptor tyrosine kinases (RTK), which 
includes EGFR (epidermal growth factor receptor – ERBB1), ERBB2 and ERBB4 (reviewed 
in (Yarden and Sliwkowski, 2001)). ERBB3 shares structural domains with other ERBB 
family members, consisting of an extracellular ligand-binding domain, a transmembrane 
domain and an intracellular tyrosine kinase domain. Unlike other ERBB receptors, ERBB3 
lacks intrinsic kinase activity and cannot auto-phosphorylate (Guy et al., 1994). Upon 
binding to a ligand, ERBB3 can be trans-activated on cytoplasmic tyrosine residues by 
forming heterodimers with other ERBB family members, of which ERBB2 is the preferred 
partner (Yarden, 2001) Tyrosine-phosphorylated ERBB3 becomes a docking site for 
downstream adaptor proteins, leading to subsequent activation of intracellular signaling 
cascades. Most notably, tyrosine-phosphorylated ERBB3 has the highest binding affinity for 
PI3K among ERBB receptors due to the nine binding docking sites for the p85 subunit of 
PI3K (Soltoff et al., 1994; Kim et al., 1994). Consequently, activation of ERBB3 frequently 
results in strong activation of the AKT signaling, a critical oncogenic stimulus whose 
aberrant activity is implicated in a wide range of cancers (reviewed in (Luo et al., 2003)).  
The ERBB family members play an important role in cancer biology. In particular, 
EGFR and ERBB2 have been actively pursued as anti-cancer targets due to their aberrant 
activation in many human malignancies (reviewed in (Hynes and Lane, 2005)). In contrast, 
the function of ERBB3 has been less appreciated due to its defective kinase activity. 
Nonetheless, accumulating evidence has implicated that ERBB3 plays a critical role in 
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cancer. Overexpression of ERBB3 often accompanies EGFR or ERBB2 overexpression and 
has been frequently detected in a variety of cancers, including breast cancers (Naidu et al., 
1998), colorectal cancer (Ciardiello et al., 1991; Maurer et al., 1998), gastric cancer 
(Kobayashi et al., 2003), ovarian cancer (Rajkumar et al., 1996) and pancreatic cancer (Friess 
et al., 1999). In ERBB2-driven tumors, ERBB3 functions as an intimate signaling partner 
that promotes the transforming potency of ERBB2, usually by activating the PI3K/AKT 
pathway (Holbro et al., 2003; Siegel et al., 1999; Soltoff et al., 1994). Recently it was 
discovered that ERBB3 couples EGFR to the PI3K/AKT pathway in non-small cell lung 
cancer (NSCLC) cells that are sensitive to the EGFR inhibitor like gefitinib (Engelman et al., 
2005). Consistent with a role in EGFR blockade resistance, ERBB3-dependent activation of 
PI3K/AKT, driven by amplification of the MET proto-oncogene, underlies the acquired 
resistance to inhibitors of EGFR in a subset of NSCLC patients (Engelman et al., 2007). 
Additionally, ERBB3-dependent signaling, through ERBB2-ERBB3 heterodimers, has been 
shown to contribute to the enhanced invasiveness of mammary tumor cells (Xue et al., 2006). 
Altogether, it has become increasing clear that in cancers driven by EGFR or ERBB2 
signaling, as seen in breast cancer and NSCLC, ERBB3 mainly functions as a signaling 
partner /substrate of EGFR or ERBB2 and mediates resistance to inhibitors of EGFR and 
ERBB2 in cancer cells. Very little, however, is known about the role of ERBB3 in other 
cancers like those developing in the colon. 
Mice with constitutional deficiency of ERBB3 die perinatally due to profound 
neuronal and cardiac defects (Erickson et al., 1997; Riethmacher et al., 1997). To investigate 
the role of ERBB3-dependent signaling during intestinal tumorigenesis, we generated a 
conditional Erbb3 allele and ablated ERBB3 specifically in the intestinal epithelium. We 
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show that ERBB3-dependent signaling has a critical role in tumor development in two mouse 
models of human colon cancer, the Apcmin mouse model of spontaneous intestinal 
tumorigenesis and the azoxymethane (AOM) mouse model of sporadic intestinal (colonic) 
tumorigenesis. In both mouse models, ERBB3 deficiency dramatically reduced tumor 
multiplicity. Unlike EGFR (Roberts et al., 2002), ERBB3-dependent signaling pathways 
regulate intestinal tumor growth; ERBB3-deficient ApcMin polyps display a significant 
reduction in size that is due to increased tumor cell apoptosis. Furthermore, we demonstrate 
that ERBB3 contributes to tumor survival via the AKT pathway since the phosphorylation of 
ribosomal protein S6, a downstream target of the PI3K/AKT/mTOR pathway, is dramatically 
reduced. Overall, these results establish the importance of ERBB3-dependent signaling 
pathway in intestinal tumorigenesis.  
3.2 Materials and methods 
C57BL/6J (B6)-ApcMin mice were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Cre transgenic mice, B6;D2-Tg(Vil-cre)20Syr (MMHCC, 01XE7) were obtained from NCI-
Frederick and maintained on C57BL/6J background as a hemizygous. Mice were fed Purina 
Mills Lab Diet 5058 under specific-pathogen-free conditions in an American Association for 
the Accreditation of Lab Animal Care–approved facility. Mice were euthanized by CO2 
asphyxiation for tissue collection.  
Genotyping. Mice with Erbb3Δ allele or Erbb3flox allele were crossed to Cre transgenic lines 
to get Erbb3Δ/+.CreTg/+ or Erbb3flox/+.CreTg/+ mice. These mice were further backcrossed to 
Erbb3Δ/+ or Erbb3flox/+ mice to get conditionally targeted Erbb3 (Erbb3floxΔ) mice. The 
genotype of each mouse was determined by PCR using mErbb3-S1 and mErbb3-AS1 for 
Erbb3. These primers give a 354-bp for the endogenous Erbb3 allele, a 235-bp for the 
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Erbb3Δ allele, a 488-bp for the Erbb3flox allele, and 193-bp PCR product specific for the 
Erbb3floxΔ allele, respectively. Mice were genotyped for the ApcMin allele as previously 
described (Roberts RB et al., 2002). Cre transgenic mice were determined using PCR with 
cre-S1, 5'-gtgatgaggttcgcaagaac-3' and cre-AS1, 5'-agcattgctgtcacttggtc-3' primers which 
brings a 278-bp PCR product.  
Tissue collection. The small intestine and colon were removed from each mouse. The small 
intestine was cut into thirds. Each segment were gently flushed with PBS to remove fecal 
material, cut longitudinally, and splayed flat. Representative tumors were scored before 
cutting in half under the dissecting microscope. One half were used for RNA extraction and 
array experiment; another half were fixed in 10% neutral buffered formalin at 4 °C overnight 
for histological analysis, or snap-frozen for use in cryo-sectioning. 
Macroadenoma counts. The tumor number and diameter were obtained for the entire length 
of the small intestine and colon, with a dissecting microscope and in-scope micrometer at 5x 
magnification. The smallest tumors that can be counted are approximately 0.3 mm in 
diameter. Tumor scoring was performed without knowledge of genotype by the investigator. 
Changes in tumor growth rate were recorded grossly as tumor size. In addition to tumor size, 
tumors were carefully scored based on number and location along the gastro-intestinal (GI) 
tract. 
Histology and Immunohistochemistry: Intestinal tissues or colon samples were rolled into 
a jelly-roll before fixing in 10% neutral buffered formalin. The processed tissues were 
embedded in paraffin and sectioned (7 µm). Every 50 µm, sections were taken and stained 
with H&E.  
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Immunohistochemical procedures were performed as described (Park et al., 2005). Colon 
tumors were rapidly dissected, fixed in 4% paraformaldehyde, and embedded in paraffin 
before cutting ten µm thick sections.  Antigen-retrieval was performed by boiling for 20 min 
in citrate buffer, pH 6.0.  Sections were treated with 0.3% hydrogen peroxide in PBS for 30 
min, washed in PBS, blocked in PBS plus 3% goat serum and 0.1% Triton X-100, and then 
incubated with primary antibodies and HRP-conjugated goat anti-rabbit secondary antibody 
(Sigma, St. Louis, MO). Antigen-antibody complexes were detected with DAB peroxidase 
substrate kit (Vector Laboratories, Burlingame, CA) according to the manufacturer’s 
protocol. The primary antibodies are anti-beta-catenin (Santa Cruz), rabbit polyclonal 
phospho-S6 Ribosomal Protein (Ser235/236) antibody (Cell Signaling #2211), polyclonal 
rabbit phospho-p44/42 MAP Kinase (Thr202/Tyr204) antibody (Cell Signaling, Danvers, 
Massachusetts).  
Apoptosis and proliferation. The apoptotic cells were detected using an ApopTag In Situ 
Apoptosis Detection Kit (Chemicon). The assay was performed according to the 
manufacturer’s manual. After deparaffinization, the tissues sections were incubated in 
proteinase K for 15 min. at room temperature. The sections were then incubated with 
terminal deoxynucleotidyl transferase (TdT) enzyme at 37oC for one hour, washed in three 
changes of PBS and incubated with anti-digoxignenin conjugate in a humidified chamber at 
room temperature for 30 minutes. The color was developed by incubating the sections with 
peroxidase substrate and then counterstained with haematoxylin for 30 seconds. For detection 
of proliferative cells, Ki-67 antibody (1: 50; Novocastra) was used. The assay was performed 
following the manufacturer’s protocols. The scoring of apoptotic and proliferative cells was 
done at x 400. A positive control slide of rat mammary glands provided by the manufacturer 
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was used as positive control for the In Situ apoptosis detection assay. For the Ki-67 staining, 
small intestinal crypt cells were used as an internal positive control. 
Statistics. The nonparametric Mann–Whitney U test was used to analyze tumor counts. One-
sided P values are given. 
3.3 Results 
3.3.1 ApcMin intestinal tumor development is dependent upon ERBB3 
To examine the potential role of ERBB3 signaling during intestinal tumorigenesis, we 
generated ApcMin mice with wildtype or intestinal epithelium specific deletion of ERBB3 
(Figure 3-1A). At three months of age, all ApcMin mice examined (n=16 ERBB3 wildtype, n= 
14 ERBB3 deficient) developed visible polyps (> 0.3mm in diameter) in the small intestine 
regardless of Erbb3 genotype. However, the number of macroadenomas in the small 
intestines of ApcMin, Vil-cre, Erbb3floxΔ mice was reduced dramatically compared with that in 
ApcMin controls (10.6 ± 6.8 vs. 91.9 ± 76.0; p < 0.00001; Figure 3-1B). This ERBB3-
dependent reduction in the number of small intestine polyps was observed in all regions of 
the small intestine, with the greatest effect in the proximal and middle part of the small 
intestine (Figure 3-1C). Whereas half of the ApcMin control mice developed at least one colon 
polyp, no colon polyps were observed in any of the ApcMin, Vil-cre, Erbb3floxΔ mice (Figure 3-
1D). Altogether, these results demonstrate that epithelial-specific ERBB3 signaling is 
important during intestinal tumorigenesis in ApcMin mice.  
 To assess the importance of ERBB3 on tumor growth, the size of the residual polyps 
in ApcMin, Vil-cre, Erbb3floxΔ mice was compared with those in ApcMin control mice (Figure 3-
1E). Polyps forming in ApcMin mice lacking intestinal epithelial expression of ERBB3 were 
significantly smaller than those forming in ApcMin control mice (average size 0.62 ± 0.48 vs. 
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0.94 ± 0.45; p< 0.0001; Figure 3-1E), suggesting that normal levels of ERBB3 signaling is 
essential for tumor growth in ApcMin mice. While only 60 % of the polyps in age-matched 
control mice were small, 87.0 % of the polyps in ApcMin, Vil-cre, Erbb3floxΔ mice were less 
than 1mm in diameter (Figure 3-1F). Similarly, the fraction of middle-sized polyps between 
1 and 2 mm in diameter was also reduced in ApcMin, Vil-cre, Erbb3floxΔ mice compared to 
age-matched controls (9.3 % vs. 38.2 %). Interestingly, a few large intestinal polyps (greater 
than 2 mm in diameter) were present on the ERBB3-deficient background, suggesting that 
their growth might be ERBB3-independent. Histological analysis of size-matched polyps did 
not reveal morphological differences related to Erbb3 genotype.  
3.3.2 ERBB3 signaling prevents apoptosis in ApcMin polyps  
The proliferative and apoptotic rates within ApcMin tumors was measured to determine 
the cellular mechanism responsible for reduced tumor size in the absence of ERBB3 in the 
intestinal epithelium. Staining with the proliferation marker Ki67 showed the proliferating 
cells in normal intestinal tissue are confined to the proliferative zone of the crypts, which was 
expanded in tumors, identified by nuclear accumulation of β-catenin, in ApcMin mice 
irrespective of Erbb3 genotype (Figure 3-2 A-F). Conversely, the apoptotic rate of tumors as 
measured by TUNEL was significantly different based upon Erbb3 genotype. An increase in 
the number of TUNEL-positive cells was observed in tumors from ApcMin, Vil-cre, Erbb3floxΔ 
mice compared tumors from ApcMin control mice (Figure 3-2 G-J). These results suggest that 
reduced tumor growth caused by epithelial deletion of Erbb3 is due to an elevated level of 
cell death, indicating ERBB3 provides a survival signal for intestinal tumor cells. 
3.3.3 ERBB3-dependent signaling is mediated by mTOR/S6. 
 68 
To investigate the molecular mechanism of ERBB3-dependent tumor cell survival, 
the activity of downstream signaling effectors in size-matched polyps from ApcMin, Vil-cre, 
Erbb3floxΔ and ApcMin control mice was examined (Figure 3-3). In ApcMin control mice, strong 
cytoplasmic immunoreactivity in non-transformed normal epithelial cells surrounding polyps 
as well as within polyps was observed for phosphorylation of ribosomal protein S6 (pS6), a 
downstream mediator of the PI3K/AKT/mTOR pathway (Figure 3-3A). However, in size-
matched polyps from ApcMin, Vil-cre, Erbb3floxΔ mice, the pS6 immunoreactivity was 
significantly reduced (Figure 3-3B). In contrast, immunoreactivity for p42/44 MAPK, which 
is associated with proliferation signal in epithelial cells, was comparable between Erbb3 
genotypes (Figure 3-3 C-D) . These results demonstrate that while signaling through p42/44 
MAPK is not effected by ERBB3 deletion, signaling via S6 is significantly reduced in the 
absence of ERBB3.  
3.3.4 ERBB3 is required in a subset of colonic tumors. 
To confirm results obtained using the ApcMin model, which predominantly develops 
small intestinal tumors, the dependency on ERBB3 signaling was also investigated in the 
azoxymethane  (AOM) model. Similar to the ApcMin model, a significant decrease in tumor 
multiplicity was observed in the absence of ERBB3 in the intestinal epithelium (Figure 3-4). 
ERBB3 wildtype mice were highly susceptible to AOM treatment: 73% of AOM treated 
mice developed one or more colonic polyp, with an average of 4.7 polyps per mouse. 
Conversely, only 30% of Vil-cre, Erbb3floxΔ mice treated with AOM developed colonic 
polyps, with an average of 2 polyps per mouse (p < 0.05). In contrast to the size-effect on 
residual polyps observed in the ApcMin mouse model, there is no significant difference in the 
size of AOM-induced colonic tumors between two groups (3.65 ± 1.6 vs. 3.58 ± 1.1; p = 
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0.92). These findings suggest that ERBB3 signaling contributes to intestinal and colonic 
tumors irrespective of the model, but a different mechanism may mediate ERBB3-
independent tumor growth depending on tumor location. 
3.4 Discussion 
Although ERBB3 lacks intrinsic kinase activity, circumstantial evidence has 
accumulated suggesting that activation of ERBB3-dependent pathways can modulate tumor 
phenotypes (Kobayashi et al., 2003; Xue et al., 2006). By generating an intestinal-specific 
deletion of Erbb3, we were able to examine intestinal polyp development in a genetic 
environment deficient for ERBB3 activity. In the ApcMin mouse model of familial 
adenomatous polyposis (FAP), ERBB3 deficiency had a profound effect on polyp number, 
reducing the mean tumor number by 88.5%. Furthermore, there was a complete absence of 
polyps in the colons from ApcMin, Vil-Cre, Erbb3floxΔ mice. This robust anti-tumor activity of 
Erbb3 deletion was confirmed in the AOM mouse model of colon cancer. ERBB3-deficiency 
significantly reduced the average size of remaining ApcMin polyps. Such size-reduction effect 
has not been observed when EGFR activity was reduced (Roberts et al., 2002), highlighting 
the unique role of ERBB3-dependent signaling in regulating tumor growth. To our 
knowledge, we provide the first direct evidence that the kinase-dead ERBB3 is pivotal for 
regulating tumor growth in vivo.  
While the extent of proliferation in ApcMin polyps lacking ERBB3 was comparable in 
those with wildtype ERBB3, a higher number of apoptotic cells were detected in the ERBB3-
deficient polyps from ApcMin mice, demonstrating an important role for ERBB3 in tumor cell 
survival. Consistent with a lack of effect on cell proliferation, ERBB3-deficient polyps, have 
normal levels of p42/44 MAPK activation, which is the predominant mitogenic signal. In 
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contrast, p70S6 kinase (S6K) activity, assayed by ribosomal protein S6 phosphorylation, is 
reduced in ERBB3-deficient polyps. S6K is a target of the mammalian target of rapamycin 
(mTOR). The mTOR/S6K pathway is associated with cell survival through regulation of cell 
cycle arrest and apoptosis (reviewed in (Asnaghi et al., 2004)). Therefore, our results indicate 
that ERBB3 signaling contributes to tumor growth by prevention of apoptosis via activation 
of mTOR/S6K. ERBB3 can couple EGFR to the PI3K/AKT upon growth factor stimulation 
(Kim et al., 1994; Soltoff et al., 1994) and PI3K/AKT lies upstream of mTOR/S6K. 
Therefore, the requirement of the ERBB3 signaling pathway in intestinal tumor progression 
could result from its unique role of linking EGFR signaling to PI3K/AKT, thus activating the 
mTOR/S6K pathway to promote cell survival. EGFR also activate PI3K/AKT through 
association with the adaptor protein GAB1 in ApcMin polyps (Moran et al., 2004). It is 
possible that PI3K/AKT is activated by EGFR via two mechanisms, association with GAB1 
and coupling with ERBB3.  Our results suggest that ERBB3 activation of PI3K/AKT is the 
major mechanism in ApcMin polyps.  
Unlike the small intestinal polyps in the ApcMin model, epithelial-specific deletion of 
ERBB3 in the AOM did not result in tumor size reduction, although the tumors were much 
fewer in number. This difference could be due in part to the fact that ApcMin mice develop 
polyps by loss of APC, while in the AOM model, tumors are induced by stabilization of β-
catenin. However, recent gene expression profiling shows that these two models are highly 
similar (Kaiser et al., 2007), suggesting that the difference in the route of tumor initiation in 
the ApcMin and AOM models likely does not contribute to molecular differences resulting in 
ERBB3 sensitivity. An alternative possibility is that a subset of colonic tumors can grow 
independently of ERBB3, similar to what we have previously observed for EGFR (Roberts et 
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al., 2002). Since Apcmin mice lacking ERBB3 in the intestinal epithelium did not develop 
colonic tumors, they either lack the ERBB3-independent class or this class is infrequent in 
the ApcMin model as opposed to the AOM model. 
In this study, we observed a profound ERBB3-dependnent reduction in polyp 
multiplicity and size. This robust anti-tumor activity of targeting ERBB3 may result from its 
unique link to PI3K/AKT and its downstream effecter mTOR. Furthermore, as ERBB3 
partners with EGFR/ERBB2 and delivers essential signals, a lack of ERBB3 would abolish 
EGFR/ERBB3 and ERBB2/3 heteromiders simultaneously, which may contribute to the anti-
tumor effects. Consequently, targeting ERBB3 and disrupting heterodimer formation, or 
using antibodies that inhibit ERBB3 heterodimerization with other ERBBs, may be more 
efficient than targeting individual receptors. Our findings also suggest that inhibition of the 
mTOR/S6 pathway, the major downstream effecter of ERBB3-dependent signaling, may be 
effective in treating intestinal cancers.  
Our study highlights the importance of regulators of intestinal tumor progression that 
are dependent on the ERBB3 signaling pathway. It will be important to determine whether 
ERBB3-dependent signaling also contributes to tumorigenesis in other cancers such as breast 
cancer, NSCLC and prostate cancer, where PI3K/AKT is strongly implicated. For this 
purpose, the conditional ERBB3 targeted allele used in this study would be an ideal tool and 
our findings illustrate the value of using mouse models to study human diseases.  
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Figure 3-1 Effects of ERBB3-deficiency on ApcMin tumor development 
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Figure 3-1 Effects of ERBB3-deficiency on ApcMin tumor development. (A) Breeding scheme 
to generate intestine epithelia-specific Erbb3 deletion. (B) Intestinal macroadenoma 
multiplicity in ApcMin mice. Each dot represents polyp number in single 3-month-old Erbb3 
wt (n= 16) and mutant (n =14) mice. (C) Frequency of intestinal polyps stratified by small 
intestine region. (D) Colonic polyp multiplicity in ApcMin mice. (E) Intestinal macroadenoma 
size analysis. Each dot represents a single polyp. (F) Size range of tumors in ApcMin mice. 
***, P < 0.0001; ****, P < 0.00001; Mann-Whitney U test. 
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Figure 3-2 Proliferation and apoptosis in ApcMin polyps from 3-month-old ERBB3 wildtype and deficient 
mice 
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Figure 3-2 Proliferation and apoptosis in ApcMin polyps from ERBB3 wildtype and deficient 
mice (A-B) Diamidino-phenylindole (DAPI) staining, (C-D) beta-catenin immunostaining 
(E-F) Ki-67 immunostaining and (G-H) TUNEL labeling with DAPI counter-staining of size 
matched intestinal polyps from 3-month-old ERBB3 wildtype and ERBB3 deficient mice. 
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Figure 3-3  Pathway analysis in ERBB3-deficient ApcMin polyps 
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Figure 3-3 Pathway analysis in ERBB3-deficient ApcMin polyps. (A-B) Immunostaining of 
phosphorylated ribosomal protein S6 (pS6) in intestinal polyps from 3-month-old Erbb3 
wildtype and  deficient mice. (C-D) Immunostaining of p42/44 MAPK in intestinal polyps 
from 3-month-old Erbb3 wildtype and  deficient mice.
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Figure 3-4 Effect of ERBB3-deficiency on AOM-induced colonic tumor development 
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Figure 3-4 Effect of ERBB3-deficiency on AOM-induced colonic tumor development. 
Colonic polyp multiplicity (A) and size (B) in azoxymethane-treated Erbb3 wildtype (n=22) 
and mutant (n=10) mice. *, P < 0.05; Mann-Whitney U test. 
 
Chapter 4 Genetic background effect on ApcMin tumor response to 
EGFR inhibition 
 
Abstract 
The ApcMin polyps forming in the hypomorphic Egfrwa2 mice appear to grow 
independently of EGFR (Roberts et al., 2002). To examine the effects of genetic 
background on EGFR-independent tumor growth, we generated F1 hybrids by 
intercrossing ApcMin  allele on C57BL/6J with Egfrwa2 allele on four congenic inbred 
strains: B6, BTBR/J, A/J and 129S1/SvImJ (129). There was significant strain-specific 
variation in tumor multiplicity and size, suggesting that BTBR/J, A/J and 129 contain 
modifiers that reduce tumor number and size. More importantly, the reduction in tumor 
number in ApcMin, Egfrwa2/wa2 mice relative to ApcMin mice carrying a wild-type Egfr allele 
varied with different genetic background. While the B6.A F1 and B6.129 F1 backgrounds 
exhibited 70% reduction in EGFR-dependent tumor growth, the C57BL/6J and B6.BTBR 
F1 backgrounds supported 50% of EGFR-independent tumor growth. These results have 
implication for understanding the genetic heterogeneity in tumor response to EGFR-
targeted therapies in human patients.  
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4.1 Introduction 
Studies into the factors contributing to colorectal cancer (CRC) have demonstrated 
that genetics  greatly affects an individual’s susceptibility to this disease (reviewed in 
(Kinzler and Vogelstein, 1996)). Familial adenomatous polyposis (FAP), resulting from a 
germline mutation in the adenomatous polyposis coli (APC) tumor suppressor gene 
(Fearnhead et al., 2001), is one of the most well characterized familial causes of CRC. 
Individuals with FAP develop hundreds to thousands of colonic polyps and have a high 
risk of developing CRC if left untreated. Variation in polyp number is thought to be 
modulated by the site of the mutation in the APC gene, environmental factors, and the 
effects of unknown genetic modifiers (Crabtree et al., 2002). Understanding the genetic 
complexity underlying susceptibility to CRC should lead to better prevention, diagnosis 
and treatment.  
A nonsense mutation at codon 850 in the mouse homolog of the APC gene, referred 
to as the multiple intestinal neoplasia allele of Apc (ApcMin), predisposes mice to intestinal 
tumorigenesis (Moser et al., 1990; Su et al., 1992). Despite the fact that the colon is 
primarily affected in FAP patients as opposed to the small intestine in ApcMin mice, the 
ApcMin model recapitulates the molecular initiating events occurring in FAP patients and 
has been used extensively as a model of human CRC. The number of polyps that arise in 
ApcMin mice is greatly influenced by genetic background (Dietrich et al., 1993; Moser et 
al., 1992). Quantitative trait analysis (QTL) identified ‘modifier of Min’ 1 (Mom1) on 
chromosome 4 as a major modifier of the ApcMin phenotype (Dietrich et al., 1993); Mom1 
affects both tumor multiplicity and size in a semi-dominant fashion (Gould et al., 1996).  
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Inbred strains carrying the Mom1 sensitive allele (Mom1s), including C57BL/6J (B6), 
BTBR/J (BTBR), A/J and 129S1/SvImJ (129), are more susceptible to polyp formation 
caused by the ApcMin mutation, whereas inbred strains carrying the Mom1 resistant allele 
(Mom1r), including AKR/J, BALB/cJ, C3H/HeJ and SWR/J, are relatively resistant to 
polyp formation. The Mom1 locus is estimated to account for about 50% of the genetic 
variation in polyp number among genetically different ApcMin/+ mice (Dietrich et al., 1993), 
indicating that other modifiers also exist. Since the discovery of Mom1, at least four 
additional Mom loci have been identified by QTL analysis (reviewed in Table 1). Along 
with the identification of Mom loci, other non-polymorphic genetic modifiers have been 
recognized by transferring mutations of interest onto a ApcMin/+ background (reviewed in 
Table 1). Modifier genes identified using the ApcMin mouse model should provide insights 
into the hereditary factors that influence CRC susceptibility and severity in humans.  
EGFR-targeted therapies, such as small-molecule-inhibitors and monoclonal 
antibodies, are now approved for use in metastatic CRC patients or are in advanced clinical 
trials for other uses. These clinical trials clearly demonstrate that the responses of CRC 
patients to EGFR-targeted therapies exhibit extensive variation, with some patients 
responding well, while the majority failing to display any benefit. With the exception of 
lung cancer, where an activating mutation in EGFR is associated with a dramatic response 
to anti-EGFR therapy, the mechanisms underlying the response to EGFR inhibitors is 
currently unknown. A important observation in clinical studies is the lack of association 
between expression of EGFR as determined by immunohistochemistry, and clinical benefit 
from anti-EGFR therapy. Interestingly, there is a striking correlation between the 
development of a skin rash, the prototypical toxicity of EGFR inhibitors, and therapeutic 
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response (Cohen et al., 2003; Janne, 2003). The underlying mechanistic explanations are 
currently unknown. 
A possible reason for the varied outcomes may be due to the pharmacological 
properties of EGFR-inhibiting drugs, with higher plasma concentrations corresponding to 
better patient response. However, the actual relationship between plasma drug level and 
clinical outcome has not been established in clinical studies. It is more likely that genetic 
differences among individuals contribute to the different responses observed with anti-
EGFR drugs. Gene expression profiling of 100 human colorectal adenomas has revealed 
that human colon tumors exhibit extensive molecular heterogeneity (Kaiser et al., 2007). 
These results suggest that although the development of CRC undergoes similar 
morphological changes (Kinzler and Vogelstein, 1996) and tumors share similar 
histopathological characteristics, the genetic and genomic events leading to malignancy are 
distinct for each tumor. Therefore, we hypothesized that genetic heterogeneity affects the 
response to anti-cancer therapeutic agents, and that genetic modifiers may be a source of 
the variability among patient responses to EGFR-targeted drugs. 
To genetically model the effects of EGFR inhibition during CRC treatment, our lab 
has used mice homozygous for the Egfrwa2 hypomorphic allele. The Egfrwa2 produces a 
receptor with a reduced kinase activity due to a substitution of a glycine for a valine 
residue near the amino terminus of the tyrosine kinase domain. Egfrwa2-encoded receptors 
have up to a 90% reduction in kinase activity depending on the assay used (Fowler et al., 
1995; Luetteke et al., 1994). Historically the Egfrwa2 allele was maintained on a B6EiC3H 
mixed background (Luetteke et al., 1993). In our laboratory, it has been bred to congenicity 
on several genetic backgrounds including C57BL/6J (B6), 129S1/SvImJ (129), A/J (A), 
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and BTBR/J (BTBR). The F1 hybrids are better at supporting pup survival to adulthood, 
allowing for detailed phenotypic analysis in these adult mice. Recent studies have shown 
that genetic background affects the development of aortic stenosis and cardiac function in 
Egfrwa2/wa2 adult mice (Barrick et al., 2007). The 129 background dominantly protects 
against calcific aortic stenosis in Egfrwa2 mice, while the B6-Egfrwa2/wa2 mice are more 
susceptible and Egfrwa2 homozygotes on the B6.129 F1 background have a mild 
phenotype. 
Since strain-based variation in phenotypes associated with reduced or absent EGFR 
activity are well established, we hypothesized that EGFR-dependent ApcMin/+ tumor growth 
would also vary by genetic background. Therefore, to identify potential strain-specific 
differences in EGFR-dependent ApcMin/+ tumor growth, we took advantage of the 
availability of four congenic Egfrwa2 strains and crossed them with B6-ApcMin/+, Egfrwa2 
mice. In this way, we generated ApcMin/+, Egfrwa2/wa2 F1 hybrids to compare tumor response 
from EGFR inhibition on multiple genetic backgrounds including B6, B6.BTBR F1, B6.A 
F1, and B6.129 F1. We found that genetic background modifies tumor multiplicity and 
size, confirming that genetic background modifiers influence tumor phenotypes. More 
importantly, strain-specific variability in tumor multiplicity associated with reduced EGFR 
activity was observed, demonstrating that genetic background affects response to EGFR 
inhibition in ApcMin/+ mice. 
4.2 Materials and methods 
Mice. C57BL/6J (B6)-ApcMin mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). Mice of the stock B6EiC3h-a/A-Egfrwa2Wnt3avt were obtained from The 
Jackson Laboratory (Bar Harbor, ME). The Egfrwa2 allele was backcrossed to the inbred 
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strains 129S1/SvImJ, BTBR/J, A/J, and C57BL/6J as previous described (Roberts, 2003). 
Mice were fed Purina Mills Lab Diet 5058 under specific-pathogen-free conditions in an 
American Association for the Accreditation of Lab Animal Care–approved facility. Mice 
were euthanized by CO2 asphyxiation for tissue collection.  
Genotyping. Mice were genotyped for the ApcMin and Egfrwa2 as previously described 
(Roberts et al., 2002; Roberts, 2003).  
Tissue collection. The small intestine and colon were removed from each mouse. The 
small intestine was cut into thirds. Each segment were gently flushed with PBS to remove 
fecal material, cut longitudinally, and splayed flat. Representative tumors were scored 
before cutting in half under the dissecting microscope. One half were used for RNA 
extraction and array experiment; another half were fixed in 10% neutral buffered formalin 
at 4 °C overnight for histological analysis, or snap-frozen for use in cryo-sectioning. 
Macroadenoma counts. The tumor number and diameter were obtained for the entire 
length of the small intestine and colon, with a dissecting microscope and in-scope 
micrometer at 5x magnification. The smallest tumors that can be counted are 
approximately 0.3 mm in diameter. Tumor scoring was performed without knowledge of 
genotype by the investigator. Changes in tumor growth rate were recorded grossly as 
tumor size. In addition to tumor size, tumors were carefully scored based on number and 
location along the gastro-intestinal (GI) tract. 
Histology and Immunohistochemistry: Intestinal tissues or colon samples were rolled 
into a jelly-roll before fixing in 10% neutral buffered formalin. The processed tissues were 
embedded in paraffin and sectioned (7 µm). Every 50 µm, sections were taken and stained 
with H&E.  
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Statistics. The nonparametric Mann–Whitney U test was used to analyze all comparisons. 
One-sided P values are given. 
4.3 Results 
4.3.1 Tumor multiplicity and size in ApcMin/+ mice on different backgrounds 
To examine the effects of genetic background on EGFR-dependent tumor growth, 
intercrosses between B6-ApcMin/+, Egfrwa2/+ and three Egfrwa2/+ congenic strains was 
established (Figure 4-1). Female Egfrwa2/+ mice from B6, BTBR, A, and 129 strains were 
crossed with male B6-ApcMin/+, Egfrwa2/+ mice. Litters were primarily produced from 
crosses in which ApcMin/+ was carried by males since ApcMin/+ females had fewer and 
smaller litters than the Apc+/+ females (unpublished observations, data not shown). 
The resulting F1-ApcMin/+ progeny homozygous for Egfrwa2 exhibited wavy coats 
and, along with ApcMin/+, Egfrwa2/+ or Egfr+/+ littermate controls, were scored for tumors 
along the entire intestinal tract at three-months of age. The distribution of tumor number in 
the small intestines among F1 hybrids with at least one wildtype Egfr allele was 
significantly shifted to few tumors compared to the parental B6 background (Figure 4-2). 
A comparison of polyp numbers from all B6 mice and F1 hybrids revealed the influence of 
BTBR, A and 129 backgrounds on polyp number (Table 2; Figure 4-3A). The average total 
tumor number for the F1 hybrids was 125.8/mouse for B6.BTBR F1- ApcMin/+ mice, which 
is significantly less that that for B6-ApcMin/+ mice (mean = 208.0 polyps/mouse, p < 0.005). 
B6.A F1 mice had a further reduction in tumor number, developing on average 62.3 
polyps/mouse (Figure 4-3A, p < 0.0001). Of the four genetic backgrounds examined, the 
B6.129 F1 background was the most resistant to polyp formation. These mice developed 
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on average 33.4 polyps (p < 0.0001). In contrast to the B6-ApcMin/+ mice that developed an 
average 1.6 colonic polyps, none of the F1-ApcMin/+ mice developed any colonic polyps 
(Table 2). Consistent with previous reports (Roberts et al., 2002), there was no difference 
in tumor number between mice carrying one or two wildtype Egfr alleles.  
The sizes of polyps were estimated by measuring their maximum diameter. The 
average diameter decreased from 1.19 mm in B6-ApcMin/+ mice to 1.03 mm in B6.A F1-
ApcMin/+ mice, with a further decrease to 0.87 mm in B6.BTBR F1-ApcMin/+ mice. 
Consistent with resistance in tumor number, B6.129 F1 mice displayed the smallest 
average polyp diameter among all four groups, averaging 0.74 mm in diameter (Table 3, 
Figure 4-3B).  
Taken together, these results suggest the existence of tumor resistance alleles 
carried by BTBR, A and 129 that can modify the B6-ApcMin/+ phenotype, resulting in a 
significant decrease in both the number and size of tumors. Although fewer in number and 
smaller in size, the polyps present in the F1 mice were histologically similar to polyps in 
B6-ApcMin/+ mice (data not shown).  
4.3.2 Tumor multiplicity in ApcMin/+, Egfrwa2/wa2 mice is modified by genetic 
background.  
Previous studies have shown that homozygosity for the Egfrwa2 allele has a 
profound effect on tumor multiplicity in adult animals on a mixed genetic background 
(Roberts et al., 2002). Consistent across all backgrounds, ApcMin/+ mice homozygous for 
the Egfrwa2 allele developed significantly fewer polyps than their respective ApcMin/+ 
littermate controls (Table 4, Figure 4-4A). Previous studies suggested that the growth of 
the residual polyps present on the Egfrwa2/wa2 background is not dependent on EGFR 
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activity (Roberts et al., 2002). On the B6 background, the polyp number decreased from 
208.0 polyps/mouse in wildtype Egfr controls to 93.4 polyp/mouse in Egfrwa2 homozygous 
mice, representing a 48% reduction in polyp number (Table 4, Figure 4-4B). A similar 
reduction was observed on the B6.BTBR F1 background, where Egfrwa2 homozygous 
ApcMin/+ animals developed an average of 75.8 polyps, compared to 125.8 polyps in 
Egfrwa2/+ or Egfr+/+ controls. On the B6.A F1 background, EGFR-independent tumor 
growth was significantly less pronounced, with Egfrwa2 homozygous mice developing an 
average of 21.4 polyps, or a 67.7% reduction compared to the 62.3 polyps in Egfrwa2/+ or 
Egfr+/+ littermate controls. On the B6.129 F1 background, Egfrwa2/wa2 mice developed a 
small number of polyps (5.9 ± 4.85) when compared to the 33.4 polyps that developed in 
wildtype Egfr controls. This resulted in a significantly higher 75.2% reduction in tumor 
number. Overall, EGFR-independent polyp growth is highly influenced by strain 
background. The B6 and B6.BTBR F1 backgrounds are more resistant to reduced EGFR 
activity, supporting about 50% of tumors being EGFR-independent,. Conversely, the B6.A 
F1 and B6.129 F1 backgrounds are more sensitive to EGFR inhibition, exhibiting an 
approximate 70% reduction in EGFR-dependent tumors, which represents about 30% 
EGFR-independent tumors. 
4.4 Discussion 
Mouse models of human cancer are powerful tools for studying cancer 
pathogenesis and susceptibility, as exemplified in the ApcMin mouse model. This model has 
an advantage over other experimental models of CRC, such as cancer cells grown as 
xenografts in nude mice, in that the phenotypes of ApcMin tumors closely resemble many 
important aspects of the initiation and early progression of human colonic tumors. First, 
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the initiation of ApcMin tumors is caused by the loss of APC expression, which molecularly 
recapitulates the most common initiation event seen in human CRC. Second, ApcMin mice 
develop numerous countable intestinal neoplasms, similar to the numerous polyps that 
develop in FAP patients. Third, the colorectal tumor phenotype in FAP patients is modified 
by known and unknown genetic factors, a trait that is mirrored in ApcMin mice. Among the 
genetic modifiers that have been localized, at least four specific ‘modifiers of min’ (Mom) 
have been characterized using inbred mouse strains that modulate the ApcMin phenotype 
(reviewed in Table 1). Inbred mouse stains can carry multiple Mom loci, with the ApcMin 
tumor phenotype being a net result of modification by all loci, in addition to non-genetic, 
environment factors. For example, the B6 strain is known to harbor both the Mom1s 
enhancer and the Mom7 suppressor alleles (Dietrich et al., 1993; Kwong et al., 2007); the 
dominant polyp-suppressing Mom7 allele is counteracted at least in part by the polyp-
enhancing Mom1s allele. Thus 100% of ApcMin/+ mice on a B6 background develop 
numerous intestinal polyps by two-to-three months of age. This phenotype contrasts 
sharply with the AKR background, where 75% of ApcMin/+ mice are tumor free at six 
months of age (Dietrich et al., 1993). The effect of the recessive, tumor enhancing Mom7 
allele in AKR is offset by the effect of the potent tumor-resistant Mom1r allele in the same 
mouse (Dietrich et al., 1993; Kwong et al., 2007). Thus, a full characterization of the 
ApcMin phenotype in different inbred mouse strains requires further analysis to identify 
novel Mom loci.  
In our study, we provide evidence for the modification of intestinal tumor 
phenotypes in B6-ApcMin/+ mice by alleles from BTBR, A and 129. In F1 hybrids carrying 
ApcMin/+, alleles coming from BTBR, A or 129 strains confer a suppression of polyp 
 92 
multiplicity and size when compared to B6-ApcMin/+. The effect of polyp resistance varied 
among the backgrounds, indicating an array of alleles within the BTBR, A and 129 
genomes affect polyp development. Previous studies have shown that all four strains 
harbor the tumor-enhancing Mom1s allele. Therefore, our observed decrease in tumor 
number on the three F1 backgrounds, when compared to B6, is not likely due to the Mom1 
genotype. Additionally, the observed decrease in the F1 hybrids is probably not a result of 
the Mom3 or Mom7 alleles, since neither exerts tumor-enhancing effects on BTBR, A or 
129 backgrounds. To determine whether the decrease in polyp number is the result of the 
tumor-resistant effects of Mom2 requires further analysis. Alternatively, since previous 
studies have shown that mutations in Dnmt1 (DNA methyltransferase) and Mmp7 (matrix 
metalloproteinase matrilysin) can influence polyp number and size in ApcMin mice 
(Cormier and Dove, 2000; Wilson et al., 1997), differences in the Dnmt1 and Mmp7 genes 
may contribute to tumor phenotype. Undoubtedly other unidentified modifier genes also 
play a significant role in ApcMin-mediated tumor development.  
The F1 hybrids used in our studies arose from a cross where parental strains were 
congenic for the Egfrwa2 allele on chromosome 11. Although we have not observed any 
differences in phenotypes between Egfrwa2/+ and Egfr+/+mice, it is possible that the size of 
the Egfrwa2 congenic region derived from the B6EiC3H mixed background could confound 
our results. Though unlikely, there may be ApcMin modifiers flanking the Egfrwa2 locus that 
are ultimately responsible for the effects we observed. Irrespectively, differences in the 
sizes of the congenic intervals would not alter the conclusions since strain-dependent 
modifiers would still be the cause of the background-dependent tumor effects of EGFR 
inhibition. 
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B6-ApcMin mice maintained in our colony develop a relatively high number of 
intestinal polyps compared with published studies. The tumor number in B6-ApcMin mice is 
commonly reported as 60-100 polyps/mouse at three-months of age, while we observe an 
average of 208.0 polyps/mouse. However, such discrepancies in tumor number could not 
have affected the validity of our results since we performed all analyses with littermate 
controls. A high tumor number in our ApcMin mice may reflect differences in 
environmental factors. For example, differences in the pathogen-free status and the gut 
microbiota may contribute to variation in polyp multiplicity. Variation in tumor number in 
B6-ApcMin mice has been reported in previous studies (Haines et al., 2005; Silverman et al., 
2002; Song et al., 2000). For example, Song et al. (2000) reported that B6-ApcMin mice 
developed an average of 24.4 polyps at three-months of age, while Silverman et al. (2002) 
reported an average number of 89.9 polyps in three-month old B6-ApcMin mice. 
Interestingly, Mom3 was identified as a novel modifier closely linked to ApcMin that results 
in a dramatic increase in polyp number (range 289-494 polyps/mouse) and a shorter life 
span (less than three-months of old) (Haines et al., 2005). Thus, another possible 
explanation  for the increase in poly number within our colony is the presence of polyp-
promoting mutations in our B6-ApcMin colony. This can be tested by crossing our B6-
ApcMin mice with B6 mice from other sources. 
A significant interest exists in defining factors that could be used to identify 
patients more likely to respond to EGFR-targeted therapeutics, so that treatments can be 
delivered to the appropriate subjects. Our studies were designed to provide a preliminary 
glimpse into the genetic complexity of this trait. Phenotypes of Egfrwa2 homozygotes 
represent the result of reduced EGFR activity in vivo, and when crossed to the ApcMin 
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mouse model of CRC, the resulting mice are an excellent model to experimentally examine 
potential causes underlying the variable response of human CRC patients to EGFR-
targeted therapies. Previous data showing modification of ApcMin tumorigenesis by the 
Egfrwa2 allele was reported for a B6EiC3H mixed background (Roberts et al., 2002).  
Although a mixed genetic background creates genetic heterogeneity that is relevant to an 
outbred human population, the random segregation of the mixed backgrounds produce 
excessive experimental variation, which can confound phenotypic analysis. To reveal the 
existence of potential modifiers that can modulate interactions between ApcMin and Egfrwa2, 
we took advantage of the availability of four congenic Egfrwa2 strains by crossing with 
ApcMin mice. In this way, we generated ApcMin, Egfrwa2/wa2 F1 hybrid mice that developed 
significantly fewer polyps when compared to their ApcMin littermates with normal EGFR 
activity, which was consistent with previously published results (Roberts et al., 2002).  
Indeed, by using congenic Egfrwa2 strains, our studies partitioned potential genetic 
background effects influencing tumor response to reduced EGFR activity; on the B6 and 
B6.BTBR F1 backgrounds a higher percentage of tumors survive with reduced EGFR 
activity than on the B6.A F1 and B6.129 F1 backgrounds. Our results strongly indicate that 
genetic differences influence the relative frequency of EGFR-independent versus 
dependent tumors. The background-associated variation in ApcMin, Egfrwa2 tumor 
phenotype closely resembles the variation in response to EGFR-targeted therapies 
observed in human patients. Being genotypically identical, each F1 hybrid population 
produces a more homogenous phenotype, which can be compared with responses to EGFR 
inhibition in a subset of patients. By changing the F1 hybrid background it is possible to 
improve our view and to dissect the variable responses seen in CRC patients.  
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Our studies represent an initial attempt to dissect the genetic complexity underlying 
variable response to EGFR-targeted therapies in heterogeneous human patients. This 
information will contribute to better patient selection, leading to improvements in the 
efficacy of cancer therapeutics. 
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Table 4-1 Genetic modifiers of ApcMin/+ mice 
Name 
(location) 
Modifier effect Mode of action Candidate genes References 
Mom1 
 
Reduces small intestinal 
adenoma size and 
number 
Control the net growth 
rate of tumors 
The secretory type 
II nonpancreatic 
phospholipase A2 
(Pla2g2a) gene 
Dietrich et al., 
1993; Gould et al., 
1996; MacPhee et 
al. 1995; Cormier et 
al. 1997, 2000 
Dnmt1 Suppress tumor 
multiplicity and growth 
rate 
Genomic 
hypomethylation 
associated with 
genomic instability 
DNA 
methyltransfer-ase 
gene 
Laird et al., 1995; 
Cormier and Dove, 
2000 
Mmp7-/- Suppress tumor 
multiplicity and size 
Not determined The matrilysin 
locus 
Wilson et al., 1997 
Blm-/- Increase tumor number Stimulate inter-
homolog recombination 
Bloom syndrome 
helicase (BLM) 
Luo et al., 2000; 
Goss et al., 2002; 
Suzuki et al., 2006 
Mlh1-/-, Msh2-
/- or Pms2-/- 
Increase tumor 
multiplicity 
Control tumor initiation DNA mismatch 
repair gene 
Shoemaker et al., 
2000; Reitmair et 
al., 1996; Baker et 
al., 1998 
Mom2 Mom2R is polyp 
resistant in both small 
and large intestine by 
90% 
NA The Atp5a1 gene Silverman et al., 
2002; Baran et al., 
2007 
Egfrwa2 Reduce tumor 
multiplicity 
Affect tumor 
establishment 
The epidermal 
growth factor 
receptor 
Roberts et al., 2002 
Rb(7/18)9Lub 
(Rb9) 
Reduce tumor 
multiplicity 
Suppress homologous 
somatic recombination 
on chromosome 18 
Robertsonian 
translocation 
Haigis and Dove, 
2003 
Mom3 Increase polyp numbers Possibly modify the 
frequency of wild-type 
allele loss at Apc: mice 
with severe disease 
showed elevated rates 
of loss 
NA Haines et al., 2005 
Mom7 >5 alleles in inbred 
strains 
Possibly affect tumor 
initiation by affecting 
somatic recombination 
NA Kwong et al., 2007 
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Table 4-2 Comparisons of average number of polyps in Apcmin/+, Egfrwa2/+ or Egfr+/+ mice on four 
different backgrounds 
 
 
 
 
 
 
 
B6 served as controls. P-values are shown from comparisons between B6 and F1 hybrids, 
using the non-parametric Mann-Whitney rank sum test.  
      Average number of polyps ± SD 
Background No. of mice Small intestine p-value Colon Total 
B6 9 206.6 ± 64.6 NA 1.6 ± 1.0 198.3 ± 66.9 
B6.BTBR F1 12 125.8 ± 34.6 < 0.005 0 125.8 ± 34.6 
B6.A F1 7 62.29 ± 27.1 < 0.0001 0 62.29 ± 27.1 
B6.129 F1 14 33.4 ± 26.4 < 0.0001 0 33.4 ± 26.4 
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Table 4-3 Comparisons of average size of polyps in Apcmin/+, Egfrwa2/+ or Egfr+/+ mice on four different 
backgrounds 
B6 served as controls. P-values are shown from comparisons between B6 and F1 hybrids, 
using the non-parametric Mann-Whitney rank sum test.  
Background No. of polyps Avg polyp size ± SD p-value 
B6 1365 1.185 ± 0.53 NA 
B6.BTBR F1 1021 0.8728 ± 0.42 < 0.0001 
B6.A F1 374 1.025 ± 0.42 < 0.0001 
B6.129 F1 406 0.7367 ± 0.38 < 0.0001  
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Table 4-4 Comparisons of average number of polyps between Apcmin/+, Egfrwa2/wa2 and Apcmin/+, Egfr+/+ 
mice on four different backgrounds 
 
 Average number of polyps ± SD 
Background Egfrwa2/wa2 Egfrwa2/+, or Egfr+/+ p value  
B6 93.38 ± 45.39 208 ± 64.5 < 0.05  
No of mice 8 9   
B6.BTBR F1 75.8 ± 50.77 125.8 ± 34.6 < 0.05  
No. of mice 15 12   
B6.A F1 21.43 ± 20.19 62.29 ± 27.1 < 0.05  
No of mice 7 7   
B6.129 F1 5.93 ± 4.85 33.4 ± 26.4 < 0.005  
No of mice 15 14   
P-values are shown from comparisons between Apcmin/+, Egfrwa2/wa2 and Apcmin/+, Egfr+/+ 
mice on each different background, using the non-parametric Mann-Whitney rank sum 
test.  
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Figure 4-1Breeding scheme to generate ApcMin/+, Egfrwa2/wa2 and ApcMin/+, Egfrwa2/+ or Egfr+/+ mice on 
four different genetic backgrounds. 
 
 
 
 
B6-Egfrwa2/+ X  B6-ApcMin/+ 
 
 
Egfrwa2/+ on  B6 
  129 
                     BTBR 
                      A 
 
 
  
B6-ApcMin/+, Egfrwa2/+ X 
A 
F1 hybrids 
GENOTYPES  CLASS 
ApcMin, Egfrwa2/wa2  test 
ApcMin, Egfr+/+  or Egfrwa2/+       control 
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Figure 4-1 Breeding scheme to generate ApcMin/+, Egfrwa2/wa2 and ApcMin/+, Egfrwa2/+ or 
Egfr+/+ mice on four different genetic backgrounds. 
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Figure 4-2 Poly number distribution in ApcMin/+ mice on different genetic backgrounds 
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Figure 4-2 Poly number distribution in ApcMin/+ mice on different genetic backgrounds. 
The polyp number in the entire small intestine and colon was determined in three-month 
old ApcMin/+ mice on (A) B6, (B) B6.BTBR F1, (C) B6.A F1 and (D) B6.129 F1 
backgrounds. Black column area represents male progeny and white column area 
represents female progeny. The Y-axis shows the number of mice within each strain 
background and the X-axis shows the number of polyps within each mouse.  
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Figure 4-3 Effect of strain background on polyp number and size in ApcMin/+ mice 
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Figure 4-3 Effect of strain background on polyp number and size in ApcMin/+ mice. The 
horizontal bar indicates the position of the mean for each group. The scatter plot in (A) 
shows the distribution of the polyp number in ApcMin/+ mice. Each dot represents the polyp 
number from a single three-month old mouse. The scatter plot in (B) shows the sizes of the 
polyps from ApcMin/+ mice.  
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Figure 4-4 Effect of strain background on EGFR-independent tumor growth in ApcMin/+ mice 
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Figure 4-4 Effect of strain background on EGFR-independent tumor growth in ApcMin/+ 
mice. (A) Comparison of the mean tumor number in three-month old ApcMin/+, Egfrwa2/wa2 
mice versus littermate controls. Grey columns represent Egfrwa2/wa2 mice and white 
columns represent wildtype Egfr littermate controls. (B) Percentage of the reduction in 
tumor number when comparing ApcMin/+, Egfrwa2/wa2 mice versus littermate controls. White 
columns, B6; checkered columns, B6.BTBR F1; horizontal stripe columns, B6.A F1; 
vertical stripe columns, B6.129 F1. (* p < 0.05, ** p < 0.005, Mann-Whitney rank sum 
test)
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Chapter 5 Conclusions and future directions
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The ERBB family of receptor tyrosine kinases consist of four closely related 
members: epidermal growth factor receptor (EGFR or ERBB1), ERBB2, ERBB3 and 
ERBB4. Signaling through ERBB family members modulates many aspects of cellular 
activity, including proliferation, differentiation, migration, apoptosis and survival (Yarden 
and Sliwkowski, 2001). As such, it is required for proper development, maintenance and 
repair of most organ systems, including skin, brain, lungs and the GI tract. Conversely, 
dysfunction in ERBB signaling is associated with a number of disease states. For 
examples, defective EGFR activity causes intrauterine growth retardation or delayed 
embryonic development while hyperactivity of EGFR and other ERBB family members 
are implicated in a variety of epithelial malignancies derived from epithelial tissues, 
including CRC. Given the proposed roles of EGFR in tumor development, a number of 
small molecule and antibody-based therapies targeting EGFR have been developed as 
therapeutic agents. Although preclinical and early clinical studies with the EGFR-targeted 
therapies were encouraging, large-scale clinical trials clearly demonstrate that the majority 
of patients do not respond. This discrepancy demonstrates that little is known about the 
mechanisms underlying tumor response to EGFR-targeted therapies. In the work presented 
in this dissertation, we used a multi-faceted approach towards identifying an anti-EGFR 
therapy response signature in CRC to indicate directions for combinatorial and targeted 
therapies for tumors resistant to EGFR inhibitors. We also established the importance of 
ERBB3 in intestinal tumorigenesis and suggest that a major role of ERBB3 is to mediate 
EGFR-independent tumor growth. Lastly, since one of the greatest challenges in 
optimizing the use of EGFR-targeted therapies is posed by patient genetic heterogeneity in 
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patients, we began an investigation into how genetic background affects tumor response to 
EGFR inhibition.  
The epithelial lining of the small and large intestine constantly undergo self-
renewal. Signaling pathways including hedgehog (HH), TGFB, fibroblast growth factor 
(FGF) and WNT are required spatiotemporally during intestinal development (Fukuda and 
Yasugi, 2002; Sancho et al., 2003; Sancho et al., 2004; Wells, 1999). The role of ERBB 
family members in intestinal development and homeostasis is intriguing based on the 
analysis of mutant mice. On genetic backgrounds that support survival of Egfr nullizygous 
mice to three weeks of age, the intestinal epithelium of surviving neonates remains intact 
with a proliferative compartments in the crypts, despite severe abnormalities in other 
epithelial tissues such as skin (Sibilia and Wagner, 1995; Threadgill et al., 1995). 
Similarly, mice homozygous for the hypomorphic Egfrwa2 allele manifest gastrointestinal 
phenotypes only upon exogenous stimulus (Egger et al., 2000; Helmrath et al., 1997). In 
mice with humanized EGFR, hEGFRKI, no phenotype in GI tract was reported, although 
they display several abnormalities in other epithelial tissues like skin and hair (Sibilia et 
al., 2003). In our study, inactivation of EGFR specifically in intestinal epithelial cells did 
not affect crypt architecture. Indeed, the proliferation rate was even enhanced in mutant 
mice. These results indicate the tissue-specific requirement for EGFR and suggest that 
EGFR is dispensable during intestinal development. Similarly, ERBB3 inactivation in 
intestinal epithelium did not lead to dramatic perturbation of the epithelia of the small 
intestine: no proliferation or apoptosis defect was observed in Erbb3 mutant mice. 
However, the minor architectural abnormalities such as the bifurcated villi phenotype in 
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ERBB3 deficient mice indicate that ERBB3-dependent signaling is involved in intestinal 
epithelial proliferation and differentiation.  
Our efforts towards identifying an anti-EGFR therapy response signature in CRC 
are particularly timely and clinically relevant, in that recent reports of completed large-
scale clinical trials clearly demonstrate a less than ideal response to EGFR blockade with 
antibodies or small molecule inhibitors. Identifying biomarkers for tumors that are 
sensitive or resistant to anti-EGFR therapies is critical to select for patients who would 
benefit most from this targeted therapy. Using mouse models as genetic tools and 
pharmacological agents, previous studies showed that a subset of intestinal tumors arose 
despite impaired EGFR activity suggesting an EGFR-independent mechanism (Roberts et 
al., 2002; Torrance et al., 2000). However, the EGFR-independent status of some tumors 
could not be shown definitely in those studies due to the residual kinase activity. In this 
study, we employed a conditional Egfr allele (Egfrtm1Dwt) enabling the generation of ApcMin 
mice with intestinal-epithelia specific Egfr deletion. We clearly demonstrate that a subset 
of ApcMin polyps grow in an EGFR-independent manner. The absence of EGFR in these 
polyps exerts little or no suppression on their growth. Indeed, the growth of these EGFR 
deficient tumors may even be enhanced. A molecular biomarker for this subset of EGFR-
independent tumors was revealed by global gene expression profiling analysis, followed by 
IHC. The signature is marked by up-regulation of components in cell cycle regulation and 
RAS-MAPK pathway genes, correlating well with a dramatic increase in p42/44 MAPK 
activity and proliferation index in EGFR-independent tumors (Figure 5-1). Ultimately, our 
goal is to probe a human CRC database with these EGFR-independent signatures to 
determine whether these mouse model-derived signatures are present in human samples.  
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Our results have important implications for EGFR-targeted therapies. Our findings 
suggest that EGFR inhibitors, either reversible or irreversible, may not be effective in a 
subset of EGFR-independent tumors that show hyperactivation of RAS/MAPK. 
Determining whether tumors are EGFR-dependent or independent will have an effect on 
our ability to make wiser clinical decisions regarding who should be given EGFR TKIs. 
Furthermore, combination therapies with MAPK inhibitors should be considered for 
EGFR-independent tumors. Additionally, it is important to determine upstream-receptor(s) 
that activate the RAS-MAPK pathway in the absence of EGFR to identify additional 
targets for combinatorial therapy. Of particular interest is the heterodimer formed by 
ERBB2/ERBB3, considering the tight co-regulation and inter-dependence within the 
ERBB family. Indeed, this idea is supported by the fact that ERBB2 and ERBB3 protein 
levels are increased in EGFR-deficient tumors. Alternatively, EGFR compensatory 
pathways could be mediated by other signals such as the insulin growth factor (IGF) 
related receptors. The IGF network is important for carcinogenesis (Samani et al., 2007). 
In particular, the IGF1 and IGF2 system is implicated in CRC (Chang et al., 2002; Slattery 
et al., 2004). In addition, the IGF1 system and ERBB pathways share downstream 
signaling mediators including RAS-MAPK and PI3K-AKT that result in cell proliferation 
and survival. Perhaps more importantly, the intimate cross-talk between IGF1 network and 
ERBB family members has been well documented (Morgillo et al., 2006; Ornskov et al., 
2006). To test these hypotheses, cell culture experiments could be set up using the pre-
neoplastic murine cell line IMCE (ApcMin/+) or human colon cancer cell lines (Caco-2, HT-
116, or HT-29). Identification of the compensatory pathways activated in EGFR inhibitor 
resistant clones generated by exposing cells to increasing concentrations of drug or by 
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transfecting cells with a dominant-negative Egfr construct (Murillas et al., 1995), could be 
used to validate our results. For human colon cancer cell lines, the recently available 
human phospho-receptor tyrosine kinase (RTK) array (R&D Systems) would allow 
comparison of how inactivation of EGFR would affect phosphorylation of other RTKs. 
Elucidation of the role for EGFR during intestinal tumorigenesis should be 
continued. One hypothesis is that the mode of EGFR action in non-transformed epithelial 
cells contributes to tumor growth. This hypothesis can be tested by histological analysis of 
the non-transformed epithelial layer enveloping the tumor in the ApcMin mice with an 
intestinal-epithelial specific Egfr deletion. Similarly, the temporal requirements for EGFR 
activity during CRC development could be addressed by using inducible CRE recombinase 
under control of the Villin promoter. Also, we have developed a B6-Egfrflox congenic line 
(> N10), which allows future studies to be carried on the B6 congenic background.  
The role of ERBB3 in cancer biology has been under-appreciated, partly due to its 
defective intrinsic kinase activity. In this study, we established the importance of ERBB3-
depdendent signaling in intestinal tumorigenesis by using a conditional knock out allele of 
Erbb3. Unexpectedly, deletion of Erbb3 caused a more dramatic suppression effect on 
both tumor multiplicity and growth in ApcMin mouse model. These results highlight the 
critical role of ERBB3, potentially by mediating the PI3K-AKT-MTOR pathway. 
Interestingly, although the majority of residual polyps forming on the ERBB3-deficent 
background have a reduced size in comparison to those on a wildtype Erbb3 background, a 
few large intestinal polyps, greater than 2 mm in diameter, were present. The proliferation 
rates, the level of p42/44 MAPK activation and the level of S6K activity are comparable in 
those with wildtype Erbb3. Determination of their sensitivity to EGFR inhibitors would be 
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revealing, since ERBB3 has been proposed as a biomarker to predict sensitivity to EGFR 
inhibitors in NSCLC, pancreatic, and colon cancer cell lines (Buck et al., 2006; Engelman 
et al., 2005). Microarray-based gene expression profiling of ERBB3-independent tumors 
would also reveal their molecular characteristics in comparison to EGFR-independent 
tumors. Consequently, elucidation of additional aspects of ERBB3 biology during 
intestinal tumorigenesis should be continued. For example, microadenoma analysis would 
reveal if ERBB3-dependent signaling affects tumor initiation.  Also, the spatio-temporal 
requirements for ERBB3 during tumor development and progression could be analyzed 
using appropriate CRE lines. ERBB3 is also required in a subset of colonic tumors induced 
by the carcinogen AOM. Since AOM tumors exhibit molecular alterations and 
morphological variation, detailed analysis of AOM colonic tumors from an ERBB3-
deficient environment could reveal the nature of histopathology and pathway disruption in 
ERBB3-independent colonic tumors. Finally, all of the ERBB3-based methodologies used 
to study intestinal tumors could be applied to models of tumors in other tissues, such as 
lung and brain, where the ERBB3 activity is strongly implicated.  
Finally, the studies presented here with different Egfrwa2 congenic lines demonstrate 
the strong background modulation of tumor response to EGFR inhibition. To initiate 
mapping experiments to identify novel modifiers of this trait, F2 offspring of ApcMin, 
Egfrwa2/wa2 mice involving B6, BTBR, A and 129 backgrounds should be produced. The 
examination of genetic background effect in tumor phenotype presented in this thesis 
serves as an initial attempt to understand the genetic components of variability in tumor 
response to ERBB targeted therapies (Jimeno and Hidalgo, 2006; Li et al., 2006). 
Advances in understanding the genetic complexity of tumor response to EGFR targeted 
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therapies should allow application of individual tailored therapy to improve the efficacy of 
targeted therapies. 
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Figure 5-1 EGFR in intestinal tumor cells− to be there or not to be there? 
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Figure 5-1. EGFR in intestinal tumor cells−to be there or not to be there? Proposed 
mechanism for proliferation and survival in EGFR-dependent /-independent intestinal 
tumors. (A) In EGFR-dependent tumors, EGFR appears to have two major functions 
during tumor development, provides a mitogenic signal by activating the RAS-MAPK 
pathway and a survival signal by activating the PI3K/AKT/mTOR through 
heterodimerization with ERBB3. Therefore, these tumors are more likely to respond to 
EGFR-inhibition by small molecule inhibitors (such as Erlotinib) or monoclonal antibodies 
(such as Cetuximab). (B) In a subset of tumors lacking EGFR, the RAS-MAPK 
components are hyper-activated, probably as a compensatory pathway for loss of EGFR. 
The activation of RAS-MAPK is likely due to an alternative signal possibly involving 
other growth factors like insulin-like growth factor-I receptor or ERBB2/3 heterodimers. 
The ERBB2/3 heterodimer is likely responsible for activating the PI3K/AKT/mTOR 
pathway, highlighting the importance of ERBB3 in promoting development of both types 
of tumors. These EGFR-independent mechanisms render tumors resistant to EGFR-
targeted therapeutics. In patients that harbor both types of tumors, combining Erlotinib or 
Cetuximab with another drug that targets IGF1R, MAPK, AKT or mTOR may lead to 
improvements in the efficacy of targeted therapies.  
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